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ABSTRACT  
Mineral oils and metal salts are commonly used as adjuvants to enhance acquired immunity. 
Recently, monoclonal antibodies (MAbs) and recombinant peptides agonist CD40 receptor have 
shown remarkable promise for induction of rapid and robust immune responses. Limitations of 
this approach MAb production costs and multiple administrations due to anti-MAb immune 
responses. Here we demonstrate the development of a unique and sophisticated DNA aptamer-
based alternative for CD40-directed delivery of universal antigens as an alternative in chickens, 
and potentially other vertebrate species. This receptor, expressed by antigen-presenting cells, acts 
as a costimulatory molecule for activated T helper lymphocytes. After initially selecting for high 
affinity aptamers of independent sequence, we utilized a polymerization process where multiple 
aptamers were simultaneously and sequentially arranged through rolling circle amplification 
products (RCA-p), potentially capable of binding multiple recognition sites and causing receptor 
clustering. Selected sequences were demonstrated to effectively activate chicken macrophage 
HD11 cell line through CD40 receptors, demonstrating proof of concept in vitro. Additionally, 
using limited proteolysis liquid chromatography electrospray ionization mass spectrometry (LC-
ESI-MS), we deduced the actual amino acid sequences targeted by these aptamer products, which 
are essential for activation. In chapter III, we produced a biotinylated version of an effective CD40-
activating RCA-p, and streptavidin-conjugated this RCA-p to a biotinylated peptide of the highly 
conserved type-A influenza peptide M2e. This conjugate was administered subcutaneously at 
either (25μg/bird) or (50μg/bird) at age 7 and 21 days. Anti-M2e IgG responses were determined 
at 14, 21, 28 and 35 days of age by ELISA. The RCA-p-M2e complex, at 50μg/bird, was able to 
induce robust seroconversion as early as 7 days post-immunization, with high antibody titer 
consistent through the end of the experiment. The lower dose, however, showed delayed responses 
   
 
and required the second administration. Taken together, these results constitute proof of concept 
for RCA-p-directed antigen delivery for peptide antigens and a potential tool for rapid generation 
of new vaccines against animal diseases.  
In chapter IV we discuss PCR artifacts that develop during traditional DNA aptamers selection 
and proposed a repetitive thermal correction cycles [(65°C/10min, 20°C/1min)x6] of the PCR. 
This may improve future selection of aptamers for similar purposes.  
  
   
 
ACKNOWLEDGMENTS 
At the beginning, I would like to express my deepest thanks to my ideal, advisor, mentor, and 
friend; Professor Billy M. Hargis for believing in me and doing whatever it takes to keep me on 
the track. Dr. Hargis, without your encouragement and support, none of this would have come true. 
Your wise guidance along this path has enriched my scientific wellbeing and made the PhD 
journey an outstanding experience. In addition, I am exceptionally grateful to Professor Young 
Min Kwon who lighted the candle when it was dark. You, and your lovely character, have 
expanded my vision to see beyond the horizon. Your showed me what it takes to maintain sedulity 
and ultimately achieve goals.  
I also would like to thank my PhD committee members; Dr. Luc R. Berghman, Dr. Kumar and Dr. 
Rosenkrans. Dr. Berghman; I am truly thankful for your continuous advising and your valuable 
inputs along my study. I deeply appreciate the contributions of yours and your team to the research. 
To Dr. Kumar, your precious comments, corrections, and guidance are deeply appreciated. Dr. 
Rosenkrans, I am thankful for your acceptance for being my PhD committee member. 
In addition, I would like to express my gratitude to Dr. Rhoads, the head of the Department of the 
Cell and Molecular Biology (CEMB, University of Arkansas), for introducing me into the CEMB 
program and for his continuous guidance and support along the past five years. 
I also express my gratitude to my government and the Iraqi Ministry of Higher Education and 
Scientific Research (MOHESR) for their support and their encouragement during my study, 
especially, the personnel of the Iraqi Cultural Attaché at Washington D.C., the personnel of the 
Middle Technical University, Baghdad, and the personnel of the Kut-Technical Institute.  
   
 
I am overwhelmed and deeply humbled to thank the staff and the faculty of the University of 
Arkansas and the Department of Poultry Science, especially Dr. Kidd, the head of the department, 
for all the facilities and friendly assistance they have provided.  
Appreciation goes to Dr. Guillermo Tellez-Isaias, Dr. Lisa Bielke, Dr. Christine N. Vuong, Dr. 
Tieshan Jiang, Dr. Jacob Lum, Dr. Leona N. Calhoun, Dr. Juan David Latorre, Dr. Ruben Merino 
Guzman, and Ms. Amanda Wolfenden for constant help and support. 
I also would like to express my gratitude to all the students at the Poultry Health Laboratory, my 
colleagues and supporters; Lucas Graham, Kyle Teague, Brittany Graham, Mikayla Baxter, Aaron 
Ashcraft, Thaina Landim De Barros, Lesleigh Beer, Makenly Elise Coles, and Callie M. Selby. 
Working professionally as one team, we were able to fulfill many great accomplishments.  
Sincere thanks also to the beautiful Lester’s, Cheryl, Howard, and Dennis. You always keep things 
going on and tolerate my mistakes.  
I also would like to show my gratitude and deep appreciation to my wife Huda Hilal Abdullah, to 
my sons; Hasan, Hussein and Ali, and to my daughter Zainab. You all got along with my decisions 
and gave me the entire support and warm environment to pursue my dream. To my family back in 
my home country who has sacrificed their time to support my PhD journey, my brother Emad, my 
sisters; Zainab, Kawther, Kawkab, Shafaa and Amal, thank you all.  
My friends, Musaab, Saeed, and Hakeem; I am very thankful for your friendship and support. 
  
   
 
DEDICATION 
This piece of work is dedicated to..  
The souls of  
My deceased father Sabr Akar Al-Ogaili  
My deceased mother and  
My martyr Master Advisor and Mentor, Dr. Ali Abdul-Hussein Shalash.
   
 
TABLE OF CONTENTS 
INTRODUCTION......................................................................................................................... 1 
CHAPTER I .................................................................................................................................. 7 
REVIEW OF LITERATURE ...................................................................................................... 7 
1.1. INTRODUCTION ....................................................................................................................... 7 
1.2. THE DISCOVERY OF VACCINES ......................................................................................... 8 
1.3. TYPES OF VACCINES ............................................................................................................. 9 
1.3.1. Live vaccines ........................................................................................................................ 9 
1.3.1.1. Live attenuated vaccines ........................................................................................... 10 
1.3.1.2. Live avirulent vaccines ............................................................................................. 11 
1.3.2. Inactivated vaccines .......................................................................................................... 11 
1.3.3. Toxoid vaccines ................................................................................................................. 12 
1.3.4. Recombinant vector vaccines and subunit vaccines....................................................... 13 
1.3.5. Conjugate vaccines ............................................................................................................ 15 
1.3.6. DNA vaccines ..................................................................................................................... 16 
1.3.7. Virus-like particles and virosomes vaccines ................................................................... 16 
1.4. THE DISCOVERY OF VACCINE ADJUVANTS AND THEIR TYPES ........................... 17 
1.4.1. Signal-1 enhancers/potentiators ....................................................................................... 20 
1.4.2. Signal-2 enhancers/potentiators ....................................................................................... 22 
1.5. CD40 RECEPTOR .................................................................................................................... 23 
1.6. CD40 RECEPTOR AGONISTS AND ANTAGONISTS ...................................................... 25 
1.7. DNA APTAMERS AS RECEPTOR AGONISTS .................................................................. 26 
1.8. CONCLUSIONS ....................................................................................................................... 28 
1.9. REFERENCES .......................................................................................................................... 31 
CHAPTER II ............................................................................................................................... 46 
Activation of Chicken HD11 Macrophage Cell Line via CD40 Receptor by Single-Stranded 
DNA Aptamers-Based Rolling Circle Amplification Products ............................................... 46 
ABSTRACT ........................................................................................................................................... 47 
2.1. INTRODUCTION ..................................................................................................................... 48 
2.2. MATERIALS AND METHODS ............................................................................................. 51 
2.2.1. Target protein, generation of recombinant extracellular domain of the chicken CD40... 51 
2.2.2. Single stranded DNA library and primers ............................................................................ 52 
2.2.3. In vitro aptamers selection procedure ................................................................................... 52 
2.2.4. PCR and dsDNA digestion into ssDNA ................................................................................. 53 
   
 
2.2.5. Cloning and sequencing .......................................................................................................... 54 
2.2.5.1. Sanger sequencing ......................................................................................................... 54 
2.2.5.2. Illumina sequencing ...................................................................................................... 55 
2.2.6. Dot-blot hybridization assay ............................................................................................ 56 
2.2.7. Rolling circle amplification .............................................................................................. 57 
2.2.8. Measuring activation of chicken HD11 macrophage cell line ....................................... 58 
2.2.9. MALDI-TOF-MS, LC-ESI-MS/MS, and LC-ESI-MS .................................................. 58 
2.2.10. Statistical analyses............................................................................................................. 59 
2.3. RESULTS AND DISCUSSION ............................................................................................... 60 
2.3.1. In vitro selection, identification and characterization of the aptamers .............................. 60 
2.3.2. Rolling circle amplification .................................................................................................... 62 
2.3.3. Nitric oxide liberation and Griess assay................................................................................ 64 
2.3.4. MALDI-TOF-MS, LC-ESI-MS/MS, and LC-ESI-MS ........................................................ 65 
2.4. CONCLUSIONS ....................................................................................................................... 66 
2.5. TABLES ..................................................................................................................................... 69 
2.6. FIGURES ................................................................................................................................... 72 
2.7. REFERENCES .......................................................................................................................... 84 
CHAPTER III ............................................................................................................................. 91 
Evaluation of a Novel Adjuvant Composed of DNA Aptamers-Based Rolling Circle 
Amplification Products Targeting Chicken CD40 Receptor and Conjugated to a Peptide 
Antigen in Broiler Chickens ....................................................................................................... 91 
ABSTRACT ........................................................................................................................................... 92 
3.1. INTRODUCTION ..................................................................................................................... 94 
3.2. MATRIALS AND METHODS ................................................................................................ 98 
3.2.1. Chickens, random mixing and management .................................................................. 98 
3.2.2. Aptamers, rolling circle amplification products and M2e peptide ............................... 98 
3.2.2.1. Aptamers. ................................................................................................................... 98 
3.2.2.2. Rolling circle amplification products. ..................................................................... 99 
3.2.2.3. Peptide immunogen. ................................................................................................ 100 
3.2.3. Immunizing complex preparation, doses, timing and routes for administration ...... 101 
3.2.4. Blood sampling ................................................................................................................ 101 
3.2.5. Quantification of specific IgG by ELISA ...................................................................... 102 
3.2.6. Statistical analyses........................................................................................................... 103 
3.3. RESULTS AND DISCUSSION ............................................................................................. 104 
3.3.1. Evaluation of the anti-Me2 antibody titers ................................................................... 104 
   
 
3.4. CONCLUSIONS AND SIGNIFICANCE ............................................................................. 105 
3.5. TABLES ................................................................................................................................... 107 
3.6. FIGURES ................................................................................................................................. 110 
3.7. REFERENCES ........................................................................................................................ 113 
CHAPTER IV............................................................................................................................ 118 
Efficient Correction of Heteroduplex DNA Formed during PCR Amplification of DNA 
Aptamer Libraries .................................................................................................................... 118 
ABSTARCT ......................................................................................................................................... 119 
4.1. INTRODUCTION ................................................................................................................... 120 
4.2. MATERIALS AND METHODS ........................................................................................... 122 
4.2.1. DNA library and primers. .................................................................................................... 122 
4.2.2. Target protein ........................................................................................................................ 122 
4.2.3. In vitro SELEX procedure .................................................................................................... 123 
4.2.4. Amplification and digestion of the DNA ............................................................................. 123 
4.2.5. Correcting thermal cycles .................................................................................................... 124 
4.2.6. Illumina sequencing .............................................................................................................. 125 
4.3. RESULTS AND DISCUSSION ............................................................................................. 126 
4.4. CONCLUSIONS ..................................................................................................................... 129 
4.5. TABLES ................................................................................................................................... 131 
4.6. FIGURES ................................................................................................................................. 134 
4.7. REFERENCES ........................................................................................................................ 138 
CHAPTER V ............................................................................................................................. 141 
5.1. CONCLUSIONS AND SIGNIFICANCE .................................................................................. 141 
5.2. REFERENCES ............................................................................................................................. 146 
APPENDIX ................................................................................................................................ 148 
  
   
 
TABLE OF FIGURES 
CHAPTER II 
Figure 2.1.  Sanger sequence results …………………….…………………………………..72 
Figure 2.2. Illumina sequence results ………………………………………………………..73 
Figure 2.3. Dot-blot assay results ……………..…….………………………………………..74 
Figure 2.4. Schematic illustration represents the process of amplification of ssDNA   
aptamers-based RCA …………………………………………………………….75 
Figure 2.5. RCA products ………………………………………………………………...…..76 
Figure 2.6. RCA products assessment ………………………………………………………77 
Figure 2.7. Identification of the MW of the chCD40ED protein by MS …….………………78 
Figure 2.8. Schematic illustration represents the experimental design   
of LC-ESI-MS ………………………………………………………………….…79 
Figure 2.9. Nitric oxide liberation from chicken HD11 macrophage cell  
line over increased concentrations of RCA products …………..………………80 
Figure 2.10. LC-MSI-MS results ………………………………….…………………………81 
Figure 2.11. Virtual tertiary structure of chCD40ED showing the   
potential aptamers linking sites …………………………………………………82 
Figure 2.12. Alignment of RCA I products …………………………………………………83 
CHAPTER III 
Figure 3.1. Schematic figure represents the design of the immune complex …………….110 
Figure 3.2. Normalized ELISA (S-N values) of the anti-M2e IgG in chicken sera at  
weekly intervals after immunization …………………………………………...111 
Figure 3.3. Normalized ELISA results representing S-N values of anti-peptide IgG in  
chicken sera at weekly intervals ……………………………………………….112 
CHAPTER IV 
Figure 4.1. Patterns of PCR byproducts that occur during SELEX procedure ………….134 
Figure 4.2. Evolution of the PCR byproducts over the SELEX rounds ..…...……………135 
Figure 4.3. Amplification of aptamers pool with single primer ………….………………..136 
Figure 4.4. Application of thermal cycles to correct PCR byproducts …….……………..137 
  
   
 
LIST OF TABLES 
CHAPTER II 
Table 2.1. DNA Library, primers, RCA templates and spacer complementary   
sequences designs ………………………………………………..……………….69 
Table 2.2. Aptamers proportion and relative frequency at each enrichment   
SELEX round ………………………………………………..……………….…..70 
Table 2.3. Candidate aptamers …………………………………………………………..…..71 
CHAPTER III 
Table 3.1. RCA Template, primer and spacer complementary sequence designs ……….107 
Table 3.2. Description of the experimental design ……………..…………………………..108 
Table 3.3. Normalized S-N values of the ELISA results of the anti-M2e IgG   
antibody in chicken sera ……………………………………...………………...109 
CHAPTER IV 
Table 4.1.  The common artifacts in PCR products after the 10 rounds of aptamers  
selection by SELEX procedure …………………………………………………131 
Table 4.2. The proportion of the short and long reads of the DNA in comparison   
to normal length sequences ……………………………………………………..132 
Table 4.3. The proportion of short and long reads of the DNA in comparison to normal  
length sequences with and without the course of the thermal correction …...133 
  
   
 
LIST OF ABBREVIATIONS 
Ags – antigens 
APCs – antigen presenting cells 
Apt – aptamer 
BCR – B-cell receptor 
CD40 – cluster of differentiation 40 
CD40L – CD40 ligand 
chCD40ED – chicken CD40 extra-domain 
CTL – cytotoxic T lymphocyte 
DAMPs – danger-associated molecular patterns 
DCs – dendritic cells 
dLN – draining lymph node 
ELISA – enzyme-linked immunosorbent assay 
HMGB1 – high mobility group box 1 
IFN-γ – interferon gamma 
IL – interleukin 
IgG – immunoglobulin G 
LC-ESI-MS – limited proteolysis electrospray ionization liquid chromatography mass 
spectrometry  
M2e – matrix protein 2 
MAbs – monoclonal antibodies 
MALDI-TOF-MS – matrix-assisted laser desorption ionization time of flight mass spectrometry 
MHC-II – major histocompatibility complex class II 
NLRs – NOD-like receptors 
NO – nitric oxide 
PAMPs – pathogen-associated molecular patterns 
RAGE – receptor of advanced glycation end products 
PRRs – pattern recognition receptors 
RCA – rolling circle amplification 
RLRs – RIG-like receptors 
   
 
SELEX – systemic evolution of ligands by exponential enrichment 
SEQ – sequence 
SCS – spacer complementary sequence 
TCR– T cell receptor 
TH – T helper 
TLR – Toll-like receptor 
VLPs – virus-like particles 
  
   
 
LIST OF PUBLISHED PAPERS 
Chapter IV 
Al-Ogaili, A. S., B. M. Hargis, and Y. M. Kwon. Efficient correction of heteroduplex DNA formed 
during PCR amplification of DNA aptamer libraries.  (Submitted for publication at BioTech.).
1 
INTRODUCTION 
High density rearing of commercial poultry has led to concentrate the effect of many infectious 
agents with resulting economic losses (Nair, 2005; Morris et al., 2007; CIWF, UK, 2007). Many 
strategies are now in use to confront the hazard of these infectious agents such as the use of 
sanitation, biosecurity, antibacterials, antiprotozoals, anthelminthics and vaccinations (Bermudez, 
2008). The emergence of evolutionary resistance of these pathogens to such drugs has restricted 
their use in modern poultry (Peek and Landman, 2003; Dibner and Richard, 2005; Hume, 2011). 
Seeking alternatives for traditional antibacterials and antiprotozoals encourages relying on other 
strategies such as vaccination to control the diseases. 
Since the first description of vaccines, the definition of vaccinology has expanded to include 
vaccine manufacturing technologies and other (non-biological) considerations such as ethnical and 
economical evaluations (Berzofsky et al., 2004; Hardt et al., 2016; Barrett, 2016). From the 
perspective of immunoprotection, vaccines must achieve minimum levels of efficacy, potency, 
purity and safety. Veterinary vaccines, however, consider economic gain as well. In more broad 
application for vaccines, vaccines can be applied to non-infectious diseases or cancers in humans. 
In contrast, in veterinary vaccinology the principle applications are for the protection against 
animal disease, there are still very significant contributions to human health and economy 
(Meeusen et al., 2007; Roth, 2011).  
The aim of vaccination is to introduce protective antigens of virulent pathogens to the host immune 
system safely.  Individually, animals may be protected by increasing the infectious dose 50 (ID50) 
for the pathogen. Epidemiologically, a phenomenon known widely as herd immunity can occur 
when most susceptible animals are protected by vaccination. This decreases the rate of 
2 
transmission within populations by decreasing susceptibility to infection, and/or decreasing the 
quantity and duration of shedding of the pathogen by infected animals. As reviewed by several 
authors (Fenton and Pedersent, 2005; Fine et al., 2011; Kim et al., 2011; Balakrishnan and Rekha, 
2018) herd immunity, defined as “The level of resistance to highly transmittable pathogen within 
population”, is also referred to as “The minimum proportion of the population that show complete 
protection against particular pathogen threat”. In completely susceptible population, the number 
of likelihood secondary infections, which result from the initial index case, is known as basic 
reproductive ratio (R0, r naught), which is also known as case reproductive rate. Three potential 
values for R0: 1) R0 > 1, the index case produces more than one new secondary infection. 2) R0 =1, 
the index case produces one new secondary infection. 3) R0 < 1 the index case produces less than 
one new secondary infection. R0 is usually higher for aerosol-transmitted pathogens as opposed to 
other routes of transmission such as fecal-oral or trans-epithelial. Based upon the principle of R0, 
it is critical to estimate the number of protected individuals within the herd to secure the population 
against epidemics.  For most pathogens, successful vaccine should induce ≥ 80% herd immunity 
(Fenton and Pedersent, 2005; Fine et al., 2011; Kim et al., 2011; Balakrishnan and Rekha, 2018).   
With most vaccines, delivering an effective immunogen requires the contribution of an effective 
and safe adjuvant or adjuvant combination to link the innate and the adaptive immune responses, 
thereby guiding and exaggerating the immune response, and/or to reduce the antigenic mass within 
vaccine. Thus, effective adjuvants increase the potency and improve the efficacy of vaccines 
(Coffman et al., 2010; Bonam et al., 2017; Garçon et al., 2011).  
Acquired immune responses begins with stimulation of innate immunity. Antigen-presenting cells 
(APCs), especially dendritic cells (DCs), link the innate and acquired immune responses. These 
cells are specialized in foreign antigens uptake, processing and presentation (Schuijs et al., 2019). 
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The recognition of foreign material by APCs is through highly conserved pattern recognition 
receptors (PRRs), which attract cognate highly conserved pathogen-associated molecular patterns 
(PAMPs) on viral, bacterial and fungal pathogens such as bacterial LPS, peptidoglycan, 
unmethylated CpG DNA and viral single-stranded RNA and DNA (Thompson et al., 2011; Juul-
Madsen et al., 2012). There are several PRRs such as Toll-like receptors (TLRs), NOD-like 
receptors (NLRs) and RIG-like receptors (RLRs). These receptors are soluble, membranous or 
cytosolic. The PRRs-PAMP interaction pathway represents signal-0 in the course of immune 
response. However, many sterile inflammatory processes appear to contradict these known 
processes, which likely indicates alternative mechanisms for induction of inflammation. In many 
cases, the immune system ignores the “non-self” antigens unless they encounter PRRs on DCs and 
they are accompanied by damage to tissue. Matzinger (1994) stated that immune response elicited 
against damage-associated molecular patterns (DAMPs) is greater than that those generated 
against PAMPs alone. Inactivated pathogens, or their highly purified products, are not ideal for 
DC activation alone; therefore, traditional adjuvants are essential for efficacy of inactivated 
vaccines. Some examples of these adjuvants are aluminum salts (aluminum hydroxide and 
aluminum phosphate), oil emulsions, and purified PAMPs or similar products (Schijns et al., 2008, 
Kool et al., 2012; Wilson et al., 2012; Bonam et al., 2017). 
Well-designed vaccines with specifically effective adjuvants are favorable in modern vaccines to 
compensate the lack of virulent action of the weakened or inactivated, or low antigenic mass as in 
subunit or recombinant vaccines. In this way, adjuvants exchange false exaggeration of low–
virulent pathogens to robust immune response (McKee et al., 2007; Garçon et al., 2011; Milligan, 
2015; O’Hagan and Fox, 2015).  
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In the first generations of vaccines, aluminum salts, oil emulsions such as water-in-oil or oil-in-
water emulsions, and synthetic biological compounds had been utilized as vaccines’ adjuvants 
interchangeably. Such adjuvants rely on their chemical composition or biological activity to trigger 
local immune ‘recognition’ response in non-specific manner (Garçon et al., 2011; Di Pasquale et 
al., 2015). With the better understanding of immune response and vaccine-host relationships, the 
era of more sophisticated vaccines has emerged. These new vaccines needed new generation of 
integrated adjuvants. This has led to development of innovated molecular adjuvants such as 
monoclonal antibodies (MAbs), cytokines and recombinant peptides. These next-generation 
adjuvants have relatively recently begun to replace first generation adjuvants in order to offer more 
flexible and more efficient vaccines (Hatzifoti and Heath, 2007; Chen et al., 2010; Knudsen et al., 
2015). For example, with recombinant vaccines, immune enhancer peptide(s) are co-expressed 
with the vaccine’s immunogen. In other subunit vaccines, the adjuvant may be linked chemically 
to the immunogen compartment to form one multi-molecule unit (Layton et al., 2009; Chen et al., 
2012; Noh et al., 2015). As stated earlier, the first generation adjuvant targeting is induction of 
innate immune response, primarily through activation of PRRs. Unlike those traditional adjuvants, 
next-generation adjuvants are designed to target immune elements that lead to induction of a 
specific immune response. Examples include adjuvants that provide agonistic activity of specific 
costimulatory molecules on the surface of the APCs or interleukins. Thus, next-generation 
adjuvants trigger and modulate specific type and/or pathway of the immune response due to their 
high specificity (O’Hagan, 2015; De Veer and Meeusen, 2011). 
There are three primary objectives for this thesis. The first part discusses the use of single-stranded 
DNA aptamers, which have been specifically selected against the extra-domain of the chicken 
CD40 receptor, as a novel immunological agonist for this receptor. The process of the aptamers 
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selection was as described by Tuerk and Gold (1990), and Ellington and Szostak (1990) 
simultaneously to produce highly specific enriched aptamers. Physiologically, the CD40 and the 
CD40 ligand (CD40L) are presented as trimers. The oligomerization of the receptor-ligand 
requires the participation of the receptor and the ligand motifs, with cross-linking of the CD40 
subunits as a requisite for activation. To simulate this naturally occurring oligomerization, and to 
exaggerate the agonistic effect of our aptamers on the chicken CD40 receptor, the aptamers were 
amplified by rolling circle amplification (RCA) technique. Technically, the RCA technique yields 
single stranded DNA, presenting tandem repeats of the template. Accordingly, RCA is ideal 
potential option for spanning and crosslinking the trimer receptor and in increasing the possibility 
of receptor stimulation.  
The rationale behind targeting chicken CD40 receptor as that this costimulatory molecule acts 
synergistically with other costimulatory molecules and cytokines to modulate the acquired immune 
response. In fact, this molecule is required to amplify the action of APCs and activated T helper 
lymphocytes. Previously, Chen and coworkers (2010, 2012) have developed an anti–chicken 
CD40 MAb that effectively stimulated a chicken macrophage cell line (HD11) and as an adjuvant 
in vivo. Therefore, we sought to mimic the action of this novel MAb by replacing it with DNA 
aptamers. Similarly, our multivalent-polyvalent RCA products-produced aptamers, containing 
repeating monomeric aptamers, caused detectable stimulation of the chicken HD11 macrophage 
cell line. 
The second objective of this dissertation is focused on the evaluation of our sophisticated 
immunological adjuvant in vivo. We tested the ability of our aptamers-based RCA products to 
increase the efficacy and the potency of an immune response against a small, low immunogenic 
avian influenza virus (AIV) extracellular domain of the matrix protein 2 (M2e) peptide. The 
6 
extracellular domain, which is a 24-amino acid peptide, forms ion channels to deliver the viral 
RNA into the host’s cell. This peptide is a highly conserved peptide among all AIVs. However, 
this peptide induces very low immune response per se (Tarigan et al., 2015; Cho et al., 2015; 
Vuong et al., 2018). We prepared an immune complex composed of streptavidin as an 
immunologically inert central molecule. The streptavidin links two biotinylated RCA molecules 
with two biotinylated synthetic M2e peptides.  In fact, we replicated our previous work with this 
particular peptide with MAb as the adjuvant. We administered this immune complex [(2)RCA-
SA-(2)M2e)] in two doses (25μg/bird) and (50μg/bird) subcutaneously to broiler chickens at two 
time intervals. The results were encouraging and demonstrated that our aptamers could enhance 
the production of anti-M2e IgG in chicken sera. 
The third objective of this thesis deals with developing a method, which able to correct the 
common artifacts that commonly develop in PCR products during DNA aptamer selection 
processes. Commonly, this method depends on thermal treatment of the PCR byproducts to reduce 
probable heteroduplex formation. The results showed significant reduction in these byproducts and 
improved linear enrichment yield of the treated pools of aptamers. 
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CHAPTER I 
REVIEW OF LITERATURE 
1.1.INTRODUCTION 
In commercial poultry industry, there are many vaccines and vaccination programs are in use. 
Successful vaccine requires utilization of the proper route of administration, the proper timing, the 
proper antigenic mass and, with many vaccines, the proper adjuvant (Schijns, 2000). Generally, 
all inactivated, subunit and inactivated recombinant vaccines strictly require the input of adjuvants. 
As discussed above, the main objective of vaccination is to introduce the foreign antigen safely to 
the immune system aiming to decrease the pathogenicity of wild-type challenge by increasing the 
infectious dose 50 (ID50).  In poultry, the purpose of vaccination is to increase the herd immunity 
or to hyperimmunize breeders in order to protect progeny by maternal antibodies (Collett, 2013). 
Inactivated vaccines, however, usually only provide protection in advance of challenge with 
pathogens causing clinical disease and rarely prevent infection per se. Consequently, this applies 
selection pressure on wild-type pathogens toward either more virulent variants of the original 
pathogen, or toward antigenic change (escape mutants). To keep in pace with this phenomenon, 
vaccine developmental is a continuous process (Gandon et al., 2001; Davison, 2008, Gimeno, 
2008). Accordingly, development of adjuvants moved hand-in-hand with that of vaccines. 
Adjuvants have relatively recently moved from first-generation inorganic salts-based, and mineral 
oil-based adjuvants to highly sophisticated molecular adjuvants (Di Pasquale et al., 2015). Better 
understanding for several branches of disciplines such as immunology, microbiology and 
molecular biology has enabled designing better adjuvants. The demand for developing new 
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generations of adjuvants is highly linked to the mechanisms by which the virulent pathogens evade 
the host immune system (Furman and Davis, 2015). 
 
1.2.THE DISCOVERY OF VACCINES 
Chronologically, the power of vaccines in controlling infectious agents was recognized by 
medieval Far East, Central Asian, and Ottoman societies (Andre, 2003; Leung, 2011; Boyston, 
2012). The generally acknowledged birth of modern vaccinology, the science of vaccines, was first 
described in Europe in 1796 by Edward Jenner who utilized cowpox virus from infected humans 
to inoculate naïve humans, which reduced the incidence and severity of smallpox in inoculated 
people (Smith, 2011). Later, Louis Pasteur developed the first live attenuated bacterial vaccine 
against chicken cholera in 1879 (Pasteur, 1880; Smith, 2012). Contributions from other scientists 
such as Paul Ehrlich and Elie Metchnikoff were considerably valuable breakthroughs. These 
significant contributions from vaccinology were the fundamental baseline that suited better 
understanding for immunology basics such as the host’s primary and secondary immune responses 
(Grieg, 1902; Gordon, 2008; Valent et al., 2016). 
Since their discovery, vaccines have become a very important economic industry. Nowadays, the 
vaccine chosen depends on several epidemiological or biological factors. Of emerging diseases, 
the time line required for initial developing a vaccine and final approval usually takes 15 years on 
average with tremendous economic investment (Beasley, 2015). Fundamentally, there are two 
major types of vaccines, live vaccines and inactivated vaccines. However, the spectrum of this 
category extends to include many vaccine subtypes. Despite a prodigious number of recent 
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publications regarding poultry vaccination, most are struggling experimentally and have not yet 
become commercially viable. 
 
1.3.TYPES OF VACCINES 
1.3.1. Live vaccines 
Commercial live poultry vaccines are available for almost all avian pathogens. Technically, the 
development of this type of vaccines vary widely. This type may include traditional live vaccines, 
recombinant live vaccines, and vectored vaccines (Schat, 2015). This type is suitable for mass 
application methods with various routes, which largely meets low labor requirements for use in 
commercial poultry (Sharma. 1999).  
Live vaccines usually require minimal antigenic mass for protection since the immunogen is 
capable of multiplication within the host. This type has great advantages economically as it 
enhances rapid immune responses and provides for protection of mucosal surfaces. In many cases 
where very high levels of immunity are desired, live vaccines precede booster vaccinations with 
inactivated and/or subunit vaccines to prime the immune response. However, the immune response 
to these vaccines in poultry often relatively short-lived, and often requires multiple booster 
vaccinations for breeders or layers prior to onset of sexual maturity.  Another disadvantage of live 
vaccination is that these vaccines are not easy to handle, they demand specific storage conditions 
and exhibit relatively short shelf life, and require specific procedures prior use such as mixing with 
skim milk or other chlorine neutralizing agents (Box, 1984; Sharma, 1999; Gimeno, 2008; Collett, 
2013). Mucosal delivery of live Newcastle disease (ND) vaccine in combination with chitosan as 
the adjuvant showed elevated level of immune response (Rauw et al., 2010).   
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1.3.1.1.Live attenuated vaccines  
This type of vaccine, such as infectious bronchitis (IB) vaccine and infectious bursal disease (IBD) 
vaccine is commonly produced by the artificial attenuation of naturally virulent pathogens (Müller 
et al., 2012; Lim et al., 2012). The process of attenuation includes the passing of the pathogen in 
abnormal host (tissue culture, embryonating chicken eggs, or media), or inducing mutation(s) by 
knocking out certain gene(s) where the pathogen loses some pathogenicity but retains infectivity. 
(Yamaguchi et al., 1996; Steel et al., 2009).  
Some bacterial vaccine strains are genetically stable such as Salmonella Typhimurium χ3985, 
however, live attenuated vaccines are not always safe because of the possibility of reverting to 
virulence when used in the natural host, as there is evolutionary pressure for selection of increased 
reproductive fitness of the pathogen.  One method to develop live attenuated bacterial vaccines is 
transposon mutagenesis, which is sometimes a limitation of live bacterial vaccines due to fair 
randomness and large number of mutations obtained (Sampson et al., 2003). On the other hand, 
the possibility of recombination of attenuated viral vaccines has to be considered with live viral 
vaccine selection. Nevertheless, there is potentially tremendous reward as compared to relatively 
modest risk in that protection from common wild-type pathogens is possible (Hassan and Curtiss, 
1996; Drake, 1999; Watanabe et al., 2008; Barrett, 2015; Eschke et al., 2018). Live attenuated 
IBD vaccine strains are resident in most poultry farms and they may interfere with the future 
vaccination and maternal immunity leading to vaccine insufficiency (Müller et al., 2012). 
A new emerging type of live attenuated vaccines prepared by insertion certain antigen(s) related 
to virulence into vector genome such as live avirulent viral or bacterial vectors. Well-known viral 
vector systems that have been used in preparation of recombinant poultry vaccines are fowlpox 
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virus, Marek’s disease, herpesvirus of turkey (HVT), ND virus and baculovirus.  Many of these 
viral vectors expressing H5 avian influenza virus (AIV) antigen or ND virus antigen have been 
shown to be successful vaccine candidates. Many bacterial vector systems have been described in 
poultry including Salmonella spp. (Curtiss and Kelly, 1987; Boursnell et al., 1990; Beard et al., 
1991; Capua and Alexander, 2008). Yeast, such as Pichia pastoris, is also a good vector candidate 
for expression the protozoan antigens such as Eimeria spp (Zhang et al., 2014). 
1.3.1.2.Live avirulent vaccines  
Many variants of certain viral or bacterial pathogens that lack significant pathogenicity but retain 
infectivity have been utilized as live vaccines. Hitchner B1 and LaSota are good examples of 
lentogenic and mesogenic strains of the ND virus, respectively (intracerebral pathogenicity index 
–ICPI of the Hitchner B1 strain is 0.2, whereas the ICPI of the LaSota is 0.4). Avirulent stains 
naturally cause subclinical infections and may go unnoticeable. The development of modern 
molecular biology has greatly increased investigations in this regard, as clinical signs are not useful 
or reliable. Choosing low virulence strains as vaccine candidates must meet certain criteria such 
as immunogenicity and stability under field conditions. (Westbury et al., 1984; Alexander and 
Senne, 2008; Kapczynski et al., 2013). Genetically engineered bacteria can serve this purpose as 
well. There are many salmonellae and E.coli in use as vaccines or vaccine vectors (see below). 
1.3.2. Inactivated vaccines  
Inactivated vaccines are composed of whole killed viral or bacterial soma or any non-replicating 
antigen vaccine such as purified peptides and recombinant subunit vaccines (Schat, 2015). Due to 
inactivation or high selection and purity of the epitopes, these vaccines lack productivity and 
pathogenicity, which in turn affect their immunogenicity. Therefore, these types of vaccine often 
12 
required adjuvant, high antigenic mass, and more than one dose to maintain sufficient duration of 
protective immune response (Meeusen et al., 2007; Marangon and Busani, 2006). With the 
inactivated vaccines, the type of the adjuvant is highly directing and interfering the most features 
of the elicited immune response. Moreover, the most robust and uniform immune responses to 
inactivated vaccines usually follow priming by live vaccines. Priming-boosting strategy is most 
commonly used for relatively long-lived poultry such as breeders or layers. The immune response 
for inactivated vaccines is different from that induced by live vaccines. In inactivated vaccines, 
cellular immune response is relatively poor whereas, humoral immune response is the dominant 
and largely influenced by the presence and type of the adjuvant (Muir et al., 2000; Schijns et al., 
2014).  Live vaccines usually administered via mucosal route and capable of inducing secretory 
antibody (SIgA), which can reduce infectivity in addition to protection from disease, whereas 
inactivated vaccines are often administered via injection (Jayawardane and Spradbrow, 1995). 
Advantages of inactivated vaccines include increased safety, low cost of development for most 
vaccines, and relatively long shelf life. Killed vaccines are prepared by the inactivation of the 
pathogen by exposure to heat, gamma radiation or chemicals such as formaldehyde and β-
propiolactone (Astill et al., 2018).  
1.3.3. Toxoid vaccines  
This type of vaccine relies on using highly purified inactivated toxins of some bacteria. Such 
bacteria are known to induce the disease by releasing toxins (exotoxins mainly). This type of 
vaccines, such as diphtheria toxoid and tetanus toxoid vaccines, are quite common in human 
medicine and veterinary medicine other than avian medicine. However, in commercial poultry, 
few publications describing toxoid vaccines against necrotic enteritis and turkey cellulitis caused 
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by Clostridium perfringens (C. perfringens) and Clostridium septicum (C. septicum), respectively. 
C. perfringens-causing necrotic enteritis is with not clearly understood pathogenicity. However, 
recent publications have described the application of toxoid anti-C. perfringens vaccines to 
chickens with variable success (Keybum et al., 2013; da Costa et al., 2013). 
C. septicum, on the other hand, causes cellulitis and dermatitis in turkey during the production 
period. The alpha toxin of C. septicum is responsible for the clinical disease. In one approach, our 
laboratory developed a formalin-inactivated and adjuvanted toxoid vaccine against this disease 
with success (unpublished data). Formalin-induced detoxification occurs through chemical 
modification of the toxin. However, the exact chemical mode of modification is not clearly 
demonstrated (Thaysen-Andersen et al., 2007). Other chemical or heat treatments are used to 
detoxify the bacterial toxins (Galazka, 1993; Jones et al., 2008). Recently, recombinant, 
genetically engineered inactivated toxins have been tested in mammals as vaccine candidates 
(Gentschev et al., 2001). This kind of vaccines requires adjuvant and the immune response against 
this kind of vaccines is similar to that of the inactivated vaccines in many facets except, the 
antibody profile against toxoid vaccines is with narrow range due to fewer epitopes (Baxter, 2007). 
1.3.4. Recombinant vector vaccines and subunit vaccines 
The strategy of preparing recombinant vaccines depends on the presence of low virulent or 
avirulent live carrier, which gained the capacity to carry and deliver heterologous antigen(s) as a 
vaccine. Genetically engineered attenuated salmonellae and E. coli strains commonly used as 
delivery systems for many vaccines antigens. Insertion of specific antigen sequences into vector 
plasmids can produce co-expression of this particular antigen with the outer membrane proteins of 
the vector such as OmpA or LamB, thus improving the immune response against the selected 
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antigen(s). Immune enhancing effectors may be designed to co-express with the vaccine antigen, 
such as co-presentation as fusion protein.  Examples include E. coli heat-labile toxin subunit B, 
avian CD154 or ligands for PRRs such as IL-4. (O’Callaghan et al., 1990; Pistor and Hobom, 
1990; Cardenas and Clements, 1993; Wolfenden et al., 2010; Sawant et al., 2011). Genetically 
engineered yeast vectors (e.g. Pichia pastoris) are able to carry other pathogenic eukaryote genes 
to overcome post-translational modification and protein folding issues in eukaryotic proteins 
(Higgins, 1995). As discussed above, several avian viruses have been utilized as vaccine vectors. 
Those are all large DNA viruses with relatively large genomes (see above). 
Genetically re-assorted live attenuated Al vaccines have been described (Nogales and Martínez-
Sobrido, 2017). To produce this kind of vaccine, embryonating eggs (or susceptible cell line) are 
co-infected simultaneously with two viral strains, e.g. wild-type HPAI virus and reference 
attenuated virus that has high replication rate in the embryonating chicken egg or cell line. Re-
assorted strains can then be selected using serological tests. Recombination between the attenuated 
and the wild type viruses will result in some combinations, which include the attenuated HA 
cleavage site with the wild-type HPAI antigens.  
Reverse genetics vaccines are another type of recombinant (live) viral vaccines. DNA viruses and 
positive-sense RNA viruses were the first targets for reverse genetics vaccines development 
(Nogales and Martínez-Sobrido, 2017). However, several systems have been described for 
development reverse genetics vaccine against influenza virus (Horimoto and Kawaoka, 2006; 
Uchida et al., 2014). In one example, the HA and NA gene segments of the wild-type virus (e.g., 
H5N1) are inserted in the backbone of the laboratory attenuated virus (A/Puerto Rico/8/34 (PR8)). 
In plasmid-based technique, each of the viral cassettes were inserted into individual vector 
plasmids, i.e. 8 plasmids represent RNA polymerase I for 8 segments cDNA, and 4 plasmids 
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expressing polymerase II for viral proteins ([RdRp complex: PB2, PB1and PA] and NP for viral 
RNP assembly). The cassettes include the viral RNA polymerase I transcription cassettes with 
polymerase promotor and terminator. Multiple basic amino acids of HA from LPAI virus replace 
the motif of the HPAI virus HA counterpart. All the viral HA, NA, and other viral proteins 
complementary DNA (cDNA) are all combined in the cassettes between the promotor and the 
terminator (Neumann et al., 2005; Uchida et al., 2014). Recently, less plasmids based systems 
have been described. Adjuvants reliable for this type of vaccines could be aluminum salts, or 
squalene-based oil emulsions or other next-generation adjuvants (Nogales and Martínez-Sobrido, 
2017). 
1.3.5. Conjugate vaccines 
Some antigens of pathogens express low immunogenicity, especially in newborns, such as 
bacterial polysaccharides and bacterial capsular polysaccharides. Because these antigens are non-
proteinaceous and less antigenic, these molecules directly activate B cells with no T cells 
recruitment (T cell-independent B cell activation). The sequelae of this pathway is absence of 
memory cells, nevertheless, antibody class switching truly occurs (von Bülow et al., 2001; Shulga-
Morskaya et al., 2004). Other pathogens have certain strategies of evading the host immune system 
by concealing their surface antigens (antigenic disguise) or inhibiting certain immunological 
pathways (Finlay and McFadden, 2006).  
As the name refers, conjugate vaccines act to link host immune responses to well identified 
immunogen in conjugation with low immunogenic antigens of a disguise invader. With this type 
of vaccines, low immunogenic haptens covalently conjugated to carrier protein render them 
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inducting well-defined immune response (Avery and Goebel, 1929; Finn, 2004; Colombo et al., 
2018). 
1.3.6. DNA vaccines 
This type of vaccine makes benefit of vector plasmids harboring pathogen encoded gene(s) 
together with promotor/terminator sequences. This plasmid promotes the expression of the 
pathogen gene(s) directly onto the recipient avian cells (Meunier et al., 2016). In fact, this type of 
vaccine is a developed recombinant vaccine; it utilizes the recipient somatic cells as the expression 
system for the vaccine antigen rather than other unicellular or viral vectors. In this way, recipient 
somatic cells will present vaccine antigens on their MHC class I molecules resulting in the 
cytotoxic T cell activation pathway. Many poultry DNA vaccines have been developed against 
avian pathogens such as anti-AI vaccine (Robinson et al., 1993; Suarez and Schultz-Cherry, 2000).  
The limitation of this approach, however, is selection of the plasmid administration tool and the 
target tissue for vaccination. Some publications describe using viable attenuated viruses or bacteria 
as the plasmid injection tools. These organisms protect the plasmid from the degradation by the 
recipient nucleases and promote the uptake of the plasmid by APCs. With these delivering systems, 
humoral immune response will develop (Sizemore et al., 1995; Liu, 2003).  
1.3.7. Virus-like particles and virosome vaccines 
These types of vaccines consist of the non-genetic antigenic components of enveloped viruses, 
which are specially prepared. Virus-like particles (VLPs) and virosomes are alike with few 
differences. They both lacking the genetic materials but retaining the outer viral coat assembly and 
native antigens (Moser et al., 2013; Lua et al., 2014). VLPs are produced by recombinant 
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technology from naked and enveloped viruses by inserting certain viral protein genes in 
recombinant vector plasmid of higher eukaryotic cells of plants, insects, yeast, or embryonating 
chicken eggs. After the vector replication, the resulted VLPs are self-assembled and could be 
harvested using several techniques such as ultracentrifugation. Eventually, the VLPs consist of all 
virus antigens and lack the viral genome (Lua et al., 2014). 
Virosomes, on the other hand, are produced in vivo from enveloped viruses such as AIV by three 
steps: 1) detergent solubilization of the viral coat, 2) removing the viral nucleocapsid by 
ultracentrifugation, and 3) elution of the detergent (Stegmann et al., 1987; Huckriede et al., 2005). 
Influenza virus VLPs and virosomes have been shown to have the ability to bind to the host cell 
membrane due to the presence of biologically active hemagglutinin (HA). The immunological 
significance of the HA is that this viral protein is a major target of anti-influenza immune response 
(Huckriede et al., 2005). Recently, recombinant HA protein of influenza virus has been expressed 
in a bacterial vector, which was then conjugated with bacteriophage-derived VLPs, showed 
protection against the challenge with the wild-type virus (Jegerlehner et al., 2013). 
 
1.4.THE DISCOVERY OF VACCINE ADJUVANTS AND THEIR TYPES 
Chronologically, the discovery of the vaccine adjuvants and their development is closely related 
to the development of inactivated vaccines (Di Pasquale et al., 2015). There are several definitions 
for vaccine adjuvants or immunological adjuvants in literature. Generally, vaccine adjuvants are 
substances that promote potency, efficacy and persistence of adaptive immune response to an 
antigen. In essence, suitable adjuvants have low or non-immunogenicity de novo. Therefore, the 
development of adjuvant is closely related to the better understanding of immunology and biology. 
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With the basic level of understanding for these sciences, simple chemical adjuvants were common. 
When the discipline of immunology and microbiology expanded, more adjuvants that are more 
sophisticated then emerged. The first attempt to develop an adjuvant was reported by Gaston 
Ramon, a French veterinarian, in 1924 when he injected inactivated diphtheria or tetanus toxoid 
in combination with starch, breadcrumbs or tapioca in horses. He recorded high anti-diphtheria 
and anti-tetanus antibodies in horses that developed abscesses at the injection site (Cited by Vogel 
and Hem, 2004). Further investigation by other scientists demonstrated that aluminum salts and 
mineral oil compounds had the similar effects. In 1932, aluminum salts were approved for use in 
human vaccines. However, this adjuvant was only successful with killed vaccines and those 
vaccine that targeting humoral immune response (as reviewed by Spickler and Roth, 2003). For 
viral pathogens or intercellular pathogens in general, the cell-mediated branch of the acquired 
immune response is required. Thus, different adjuvants were required. Unlike old killed vaccines 
which may harbor traces of elements of the pathogen that can serve as a casual adjuvant, modern 
highly purified vaccines are less successful in induction an immune response de novo (O’Hagan, 
1997; Schijns, 2000). It is difficult task to create one adjuvant category because of the huge 
diversity of these molecules (biologically and chemically) and rudimentary understanding for 
required modes of action. However, with recently improved understanding of molecular 
immunology, the mechanisms of actions of adjuvants became clearer. Adjuvants can now be 
classified according to their chemical composition or their immunological action. As described by 
Schijns (2000), Schijns and co-workers (2008), and Schijns (2017), there are two immunological 
groups of adjuvants described as signal-1 enhancers/potentiators and signal-2 
enhancers/potentiators (please see below).  
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Signal-1 potentiators’ category includes TCR-peptide-MHC class II molecular interactions. 
However, this interaction is not always sufficient to ignite full immune response process because 
signal-0 (danger signal) is also required (signals 0, 1, 2 and 3 models are reviewed in detail below). 
Traditional adjuvants such as aluminum salts and oil emulsions that prolong the vaccine antigen 
release from the inoculation site are all under this category (Schijns, 2017). Unless adjuvants are 
included, inactivated vaccines may be ignored by the acquired immune system despite the presence 
of sufficient antigenic mass. It is now well understood that innate immune responses provides 
signal-0 via the interactions of PRRs-PAMPs (Spickler and Roth, 2003). As stated earlier, DAMPs 
could provide robust innate immune responses in sterile inflammation. These molecules, such as 
extracellular high mobility group box 1 (HMGB1), and extracellular heat shock proteins (HSPs), 
show the ability to trigger innate immune response via receptor for advanced glycation end 
products (RAGE) and TLR receptors, respectively (Matzinger, 1994; Tang et al., 2012). It is now 
well understood that the following adjuvants category depends on adjuvant input within the time 
course of innate and acquired immune response to adjuvanted vaccines. The exception are VLPs 
and virosomes vaccines. These vaccines may elicit protective immune response in absence of 
adjuvants (viral genomic RNA or DNA, or artificial adjuvant). This might be attributed to the 
highly concentrated and highly ordered epitopes that show tandem repeat order. In addition, these 
vaccines directly activate APCs (Schijns, 2017). 
Signal-2 potentiators, on the other hand, act to stimulate the APCs (DCs in particular) with 
concurrence of costimulatory molecules upregulation. These molecules act as adjuvants via 
agonistic engagement with specific type of PRRs on the APCs (Schijns, 2017). 
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1.4.1. Signal-1 enhancers/potentiators  
Adjuvants under this category act directly by influencing the introduction of the vaccine antigen 
to innate immune cells, more specifically, APCs. This category includes the adjuvants that extend 
the availability time of the vaccine antigen, and create danger signal to attract the interested 
inflammatory and innate immune cells. For example, this kind of adjuvants may include aluminum 
salts, oil emulsions, TLR agonists, interferon (IFN-γ), and interleukins (IL-1β) (Gupta et al., 
2014a; Gupta et al., 2014b; Ramakrishnan et al., 2015). The introductory effect of these adjuvants 
has to be accompanied by danger signal through irritation and local damage. As discussed above, 
natural immune response starts with signal-0, which represented by the DAMPs/PAMPs 
interaction with PRRs on the DCs. Next, DCs become mature with changed cytokine profile, which 
lead to homing of the mature DCs to marginal draining lymph nodes (dLN). Naïve T cells, on the 
other hand, do not have the receptors or cytokines profile to leave the secondary lymphoid organs 
or draining lymphatic vessels in mammals. Within the secondary lymphoid organs, naïve T cells 
only encounter processed and presented foreign antigen by mature DCs homing to dLN in 
mammals. DCs require input from injured tissue and other inflammatory cells in the form of 
chemokines and cytokines to direct lymphocytic chemotaxis.  
As discussed above, PAMPs-PRRs and/or coupling with DAMPs are crucial events to trigger 
innate immune responses (Coffman et al., 2010; Matzinger, 1994). The nature of the pathogenic 
antigen determines the course of the subsequent acquired immune response. When foreign antigens 
are introduced parenterally, they must cause stimulation of DCs to act as a vaccine. For example, 
with aluminum salts-based adjuvants, the traditional thinking has been that these adjuvants simply 
adsorb and slowly release the antigen locally. However, they also offer a degree of irritation, 
stimulating innate immune responses, thereby stimulating immature DCs via their PRRs. This 
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phenomenon provides multiple mechanisms for interaction of vaccine antigens with DCs. In this 
way, adjuvants such as aluminum salts may promote a prolonged immune response signal-0 
(Marrack et al., 2009). Evidence suggests that aluminum salts result in local necrosis and uric acid 
production. This pathway leads to stimulation of DCs via NOD-like receptor (NLRs) and NLRP3 
inflammasome activation (Mutwiri et al., 2011). However, several more recent observations 
suggest that the actual mechanisms involved may be more complicated. For example, in mammals, 
the cascade of DC innate activation has been reported to be dependent upon inflammasome 
formation rather than TLRs interaction. NLRP3 inflammasome signaling could instruct the 
production of pro-inflammatory cytokines such as IL-1β and IL-18 by macrophages (Eisenbarth 
et al., 2008; Vance et al., 2009; Wilson et al., 2014). As described above, this pathway is dependent 
upon priming with PAMPs-PRRs. Not all aluminum salts-based vaccines carry microbial PAMPs 
(Savelkoul et al., 2015).  
Recent studies have shown that aluminum salts have the capacity for complement fixation, 
mammalian eosinophil and neutrophil recruitment and granulomatous lesion formation but not 
direct DC maturation (Shamri et al., 2011; Ghimire, 2015). Thus, the ability of aluminum salts to 
mediate PRRs is questionable. Moreover, the mode of action of aluminum salts-based, oil-based 
emulsions, Freund’s complete and Freund’s incomplete adjuvants is not well understood. Instead, 
aluminum salts require synergistic effect of LPS to stimulate the action of caspase-1 in DCs with 
subsequent release of IL-1β and IL-18. Conversely, MyD88-knockout mice, which lack IL-1β and 
IL-18, were able to respond normally to aluminum salts-based adjuvanted vaccines (Franchi and 
Núñez, 2008; McKee et al., 2009; Mosaheb et al., 2017). Studies on water-in-oil emulsions 
suggested that the vaccine antigen enclosed in the aqueous phase of the adjuvant, whereas oil-in-
water adjuvants trap the antigen in the oil phase. Therefore, hydrophilic antigens work better with 
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water-in-oil adjuvants and hydrophobic antigens work better with oil-in-water adjuvants. Oil 
emulsions and Freund-based adjuvants suggested to work by depot-slow release of the antigen 
hypothesis (Stills, 2005; Awate et al., 2013). Furthermore, there is solid evidence that the DCs 
function to carry a vaccine antigen with labeled adjuvant to marginal LNs in mammals (Herbert, 
1968; Dupuis et al., 1998; Jansen et al., 2007). 
1.4.2. Signal-2 enhancers/potentiators  
As stated above, PRRs are the receptors responsible for recognizing the cognate PAMPs (see 
above). These receptors are the keystone in innate immune recognition pattern (O’Hagan et al., 
2017). In fact, PRRs are highly conserved among vertebrates and are able to recognize their 
counterparts of highly conserved PAMPs of bacteria, viruses and fungi. The class of PRRs 
involved in initiation of the innate immune response determines the PPR-dependent acquired 
immune response. For example, Toll-like receptors (TLRs) guide acquired immune responses 
differentially from those guided by NLRs with initiation of innate immunity. Conversely, 
Matzinger (1994) hypothesized that the immune system is more activated by danger signals rather 
than non-self signals. Accordingly, danger signal recognition via DAMPs, leads to direct or 
indirect upregulation of APC costimulatory molecules (signal-2). 
Unlike signal-1 enhancer adjuvants, signal-2 enhancer adjuvants act to deliver the vaccine antigen 
directly to immune cells instead of storage behavior. Adjuvants under this category act by altering 
the cytokines profile and/or expression of costimulatory molecules (Sprikler and Roth, 2003). 
When humoral immune response is required for protecting against certain types of pathogens, 
cytokine profiles play the critical role in determining the antibody abundance and isotype. 
Different antibody isotypes harbor different abilities in neutralization and opsonization of the 
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pathogen and complement fixation. Cytokines such as interleukins (IL-1β, IL-2 and IL-18), type I 
interferons (α and β), MGF and G-CSF may be processed chemically or by co-expression with the 
pathogen gene to act as potential adjuvants (Hilton et al., 2002; Rahman and Eo, 2012). For 
example, type I interferons induce upregulation of CD40, CD80, CD86, MHC class I and class II 
molecules. When recombinant influenza vaccine carrying interferon was administered, significant 
increased levels of protection were reported (Proietti et al., 2002; Hervas-Stubbs et al., 2011).  
Our lab group have established that using extracellular HMGB1 as an adjuvant was quite 
successful (Kuttappan et al., 2013). Extracellular HMGB1 is a ligand for RAGE, which mediates 
DC maturation (Grover et al., 2013). Finally, costimulatory molecule receptor-ligand pathways 
have been recently investigated, and shown to be effective. For example, anti-CD40 MAb showed 
sustainable adjuvant effects in this category in mice (Hatzifoti et al., 2008). More recently, an anti-
CD40 MAb has been demonstrated to be similarly effective in chickens when linked to a variety 
of antigens (Chen et al., 2010; Chen et al., 2012; Chou et al., 2016; Martin et al., 2017; Vuong et 
al., 2018). 
   
1.5.CD40 RECEPTOR 
Communication among cells occurs physically and chemically via various receptors and ligands. 
Cell interaction and cell signaling are essential tasks to induct, sustain and terminate an immune 
response. Several molecules have been characterized as costimulatory molecules within the 
adaptive immune response. Cluster of differentiation 40 (CD40) is one of these molecules that 
participates significantly in the course of developing a humoral immune response. This molecule 
was firstly reported as a surface antigen protein expressed on human bladder carcinoma cells 
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(Koho et al., 1984). Further studies have shown that this molecule is naturally expressed as a B-
lymphocyte cell surface receptor that regulates humoral immune response (Paulie et al., 1985), as 
well as on other APCs. (Stout and Suttles, 1996; van Kooten and Banchereau, 1997; Ma and Clark, 
2009; Suttles and Stout, 2009). This receptor, which belongs to tumor necrosis factor receptor 
(TNF-R) superfamily, is a 48kDa glycoprotein with extracellular domain, leader sequence, 
transmembrane domain and intracellular domain. The extracellular domain is a trimer whereas; 
the cytoplasmic domains are several TNFR-associated factors (TRAFs) (Braesch-Andersen et al., 
1989; Bajorath and Aruffo, 1997; McWhirter et al., 1999). 
The ligand for the CD40 receptor (CD154) is a 34-39kDa protein with trimeric extracellular 
domain that belongs to TNF superfamily. The ligand is transiently expressed by activated CD4+ 
TH lymphocytes. However, recent studies have shown that CD40L (CD154) is also expressed on 
DCs and activated B cells. In DCs, the regulation of adaptive immune response via this receptor 
is well identified (Ma and Clark, 2009). As described above, the expression of CD40 and CD40L 
requires proceeding signal-0 and signal-1. Naïve B cells become activated through the engagement 
of B cell receptors with foreign peptide antigen at the periphery, thereby acting as the APC for 
resting T cells at the T zone within dLN.  
Engagement of TCR on naïve T cell with presented peptide that is in association with the MHC 
class II molecule on the B cell leads to activation and differentiation of the naïve T cells into TH 
cells. Both activated cells begin to express costimulatory molecules such as CD40, CD80, CD86 
and MHC class II molecules on B cells as well as transient expression of CD40L on activated T 
cells. Therefore, activated T cells also participate in activation of B cells via CD40-CD40L 
pathway. The subsequent downstream cell signaling within activated B cells is differentiation into 
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plasma cells, which produce abundant antibodies with high affinity and specificity to the target 
antigen, as well as leading to memory cell development (Parker, 1993; Ratcliffe, 2008). 
 
1.6.CD40 RECEPTOR AGONISTS AND ANTAGONISTS 
Most publications on CD40 agonists and antagonists are dealing with mammalian anti-cancer 
therapy research and autoimmunity, respectively (Vonderheide et al., 2013; Karnell et al., 2018). 
Recent studies showed that the use of different agonistic MAbs to CD40 might lead to induction 
of adaptive immune responses or mediate cytotoxicity against specific CD40-expressing 
lymphomas. These approaches are promising tools in cancer immunotherapy (Tai et al., 2005; 
Vonderheide and Glennie, 2013). Activation of tumor-associated macrophages via CD40 revert 
the suppressive action of tumor cells, and render them active antitumor phagocytes instead of 
tumor-promoting cells. CD40 agonists stimulate other APCs by triggering tumor-specific T cell 
immune response (Beatty et al., 2011; Palma and Lewis, 2013; Vonderheide et al., 2013). Anti-
CD40 MAbs, soluble CD40L or viral-vector expressing CD40L have been shown to mimic 
humoral or cellular immune responses to a variety of T cell-dependent or independent immune 
responses (Hanyu et al., 2008; Thompson et al., 2015). 
Anti-CD40 MAbs seem to be promising vaccine adjuvants that act alone or in combination with 
other molecules in several species (Thompson et al., 2015; Martin et al., 2017). In one approach, 
our group has recently shown that targeting chicken CD40 receptors for activation with anti-
chicken CD40 MAb was extremely successful for induction of robust and long lasting immune 
responses (Chen et al., 2010; Chen et al., 2012; Chou et al., 2016). Anti-CD40 MAbs have also 
been demonstrated to induce either agonistic or antagonistic effects dependent upon site(s) of 
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CD40 binding (Yu et al., 2018). Clearly, anti-CD40 agonistics are promising immunological 
adjuvants (Martin et al., 2017).  
 
1.7.DNA APTAMERS AS RECEPTOR AGONISTS 
Aptamers, artificially prepared oligonucleotide molecules or peptides, have drawn attention as 
alternatives to MAbs in many biological systems with multiple advantages (Reverdatto et al., 
2015). Each RNA or single-strand DNA (ssDNA) molecule expresses a unique three-dimensional 
structure according to its sequence. The almost infinite number of folding patterns created by 
unique nucleotide sequences creates multiple possibilities, with low frequency, which are able to 
uniquely bind to specific complex molecules such as receptors. By creating random ssDNA 
sequences and sequentially enriching those expressing binding to a target molecule, individual 
aptamers can be selected with high affinity for those targets.  This phenomenon enables aptamers 
to have affinities and specificities to target molecules that may exceed those of MAbs to the same 
target molecules. In practice, aptamers are identified via an in vitro repetitive selection process 
from a combinatorial oligonucleotides library, which is abbreviated as SELEX, standing for 
Systematic Evolution of Ligands by EXponential enrichment. The characterization of the enriched 
aptamers is with mathematical prediction via bioinformatics. Conversely, MAbs require animals 
for production. Other characteristics of aptamers include thermostability, chemical resistance and 
reproducibility. For example, they can be shared as a known sequence rather than a biological 
product, providing an additional advantage over MAbs (Tuerk and Gold, 1990; Ellington and 
Szostak, 1990; Irvine et al., 1991; Hermann and Petel, 2000; Baker, 2015; Bradbury, 2015; Jeddi 
and Saiz, 2017). There are many proposed and proven uses of selected aptamers including 
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therapeutic applications, purification of molecules, studying biological pathways, and developing 
biomarkers (Centi et al., 2007; Dollins et al., 2008; Kunii et al., 2011; Zhang et al., 2012; Wang 
and Li, 2013). 
Few publications describe aptamers as potent immunological adjuvants. Pastor and coworkers 
(2013) showed that anti-CD28 aptamers could act as a potential adjuvant. They described different 
aptamers that acted to stimulate or block the receptor. Another study has shown that anti-OX40 
aptamers could enhance the action of an antitumor vaccine (Weinberg, 2002).   
There is currently a dearth of published information discussing the economic value of adjuvants. 
Generally, optimal price of vaccine/vaccination unit to the price of the protected 
individual/production is critical in poultry. Herein, cheaper vaccines with cheaper application 
processes are favorable for commercial poultry. Monoclonal antibody use as a commercial vaccine 
adjuvant would likely be cost-prohibitive for commercial poultry. As anti-CD40 MAb have been 
demonstrated to be highly effective in poultry (Chou et al., 2016; Vuong et al., 2018), the potential 
for cost-effective mimicry of this response through selected anti-CD40 aptamers is potentially 
appealing.   
Even within well-accepted commercial adjuvants, costs of specific adjuvants vary widely, as do 
their efficacy and duration of elicited response.  For example, aluminum salts are markedly less 
expensive than emulsion oils, but the immune response is generally higher with oil-based 
adjuvanted vaccines (Astudillo and Auge de Mello, 1980 as cited by James and Rushton, 2002; 
Rushton, 2009). Thus, it is possible that effective aptamer-directed antigen delivery methods could 
potentially be appealing from both a cost and efficacy perspective, although this has not been 
evaluated. 
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1.8.CONCLUSIONS 
The increasing demand for antibiotic-free animal products in concurrence with emergence of 
antibiotic resistant bacteria, and the emergence of highly devastating viral pandemics have 
contributed to strong efforts toward vaccination-mediated prophylaxis for commercial poultry 
(Hoelzer et al., 2018; de Vries et al., 2018). Developing new vaccines and updating old vaccines 
is a promising field within animal agriculture and for poultry production specifically. Improved 
understanding of poultry pathogens and avian immune responses will likely enable development 
of increasingly sophisticated and more effective vaccines. Subunit vaccines are currently the most 
intensely investigated vaccines for poultry. However, such vaccines are less immunogenic and 
need the participation of adjuvant to achieve effective immune response (Garçon et al., 2011; 
Miligan, 2015).  
Adjuvants are currently required for most candidate subunit vaccines, due to the relatively low 
immunogenicity of these antigens, and adjuvants are required for durable responses for vaccination 
of pullets intended to protect breeders for approximately one year of production. Currently used 
traditional commercial vaccine adjuvants typically enhance the immune response by facilitating 
the engulfment of the vaccine antigen. This enhancement is by promoting signal-1 or signal-2 
during the adaptive immune response. Signal-1 enhancer adjuvants promote the engulfment of the 
foreign antigen via PRRs and may promote other innate immune response elements such as 
complement fixation (Coffman et al., 2010; Schijns, 2017). Signal-2 enhancer adjuvants target 
costimulatory receptors such as CD40 as one of the central molecules in the adaptive immune 
response activation. This costimulatory molecule orchestrates the T-dependent humoral immune 
response by providing co-stimulation to both T cells and APCs. Targeting this molecule enhances 
the action of APC in multi-dimensional ways. On DCs, this molecule acts a costimulatory receptor, 
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which when engaged with CD40L on activated T cell; both cells will pass through downstream 
activation resulting in differentiation of activated T cell into TH cell subsets such as TH1, TH2, TH9, 
TH17 or Treg (Ma and Clark, 2009). The TH subset differentiation depends on the nature of the 
antigen that affects the cytokine profile of the DC, which in turn determines the TH subtype. For B 
cell mediated antibody production, isotype switching and affinity maturation are all events, which 
follow CD40-CD40L interaction through the T-dependent B cell activation pathway. Involvement 
of B cell presentation of certain antigens for naïve T cells is an essential event for effective humoral 
immune responses (Parker, 1993; Ratcliffe, 2008).  
Several publications have showed that agonists for the CD40 could trigger an immune response 
resembling the natural immune response against wild-type pathogens. These CD40 agonists could 
act successfully as adjuvants such as soluble CD40L and anti-CD40 MAbs. The MAb-adjuvanted 
vaccines showed robust immune response with haptens of low immunogenicity. One of the 
limitations of using MAbs as an adjuvant for commercial poultry vaccines is the cost and handling 
requirements of this kind of adjuvanted vaccine. Additionally, the MAbs are immunogenic 
themselves and may interfere with subsequent booster-initiated immune responses (Chen et al., 
2010; Chen et al., 2012; Chou et al., 2016; Martin et al., 2017; Vuong et al., 2018).  
This dissertation describes investigations related to selection and design of anti-CD40 aptamers as 
a potential alternative to MAb-directed CD40 activation and presentation of antigenic cargo.  The 
potential advantages of this approach could include improved stability, low cost of production, and 
robust induction of immune responses as compared to traditional adjuvants for chickens.  
In broader range, our anti-CD40 aptamers could lead to new insight of receptor activation. For 
example, the activation of the CD40 receptor by ligation with CD40 agonists on tumor-associated 
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macrophages – M2 cells reverts the inhibitory effect of these cells on cytotoxic T cell and enhance 
phagocytic activity of the M1 TAMs (Hoves et al., 2018). 
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ABSTRACT 
Cluster of differentiation 40 (CD40) is a costimulatory receptor molecule on antigen presenting 
cells (APCs) that mediates specific immune responses when interacts with its ligand 
(CD40L/CD154) on activated T helper cells. Previously, anti-chicken CD40 monoclonal antibody 
has been proven to induce similar effect on the APCs. In this study, we aimed to mimic the 
naturally or artificially occurring APCs activation by developing DNA aptamer agonist to the 
CD40 receptor. First, we developed DNA aptamers to chicken CD40 extra domain as a bait. Next, 
the selected aptamers served as templates for rolling circle amplification (RCA) procedure. RCA 
products would enhance aptamers effect by spanning larger space with stronger binding affinity to 
CD40. Eight DNA aptamer candidates were used to generate four RCA products (namely, RCAI-
RCAIV). The signal transduction ability of the RCA was evaluated on chicken HD11 macrophage 
cell line. The results showed that all RCA products (RCA I in particular) were able to activate the 
macrophage HD11 cell line. Additionally, limited proteolysis liquid chromatography electrospray 
ionization mass spectrometry experiment showed inhibition in trypsin digestion of CD40 by 
Aptamers and determined the amino acid sequences where the candidate aptamers attach the CD40 
receptor. Our work could bring new insight into the use of aptamers, in the form of RCA, for 
stimulation/blocking of many receptor-ligand interactions. 
 
Keywords: Chicken CD40 receptor agonist, DNA aptamers, Rolling circle amplification, Mass 
spectrometry 
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2.1.INTRODUCTION 
Cluster of differentiation 40 (CD40) was firstly reported as a surface antigen protein expressed on 
human bladder carcinoma cells (Koho et al., 1984). Further studies have shown that this antigen 
is naturally expressed as a B-lymphocyte cell surface receptor that regulates humoral immune 
response. Now, CD40 is a costimulatory receptor that expressed on variety of immune and non-
immune cells including antigen-presenting cells (APCs) and regulates adaptive immune response. 
The ligand for the CD40 receptor (CD40L/CD154) transiently expressed by activated CD4+ T 
helper (TH) lymphocytes (Amitage et al., 1992; Banchereau et al., 1994; Foy et al., 1996; Stout 
and Suttles, 1996; van Kooten and Banchereau, 1997; Bajorath and Aruffo, 1997; Ma and Clark, 
2009; Suttles and Stout, 2009; Kawabe et al., 2011).  
Upon maturation, DCs express CD40 as costimulatory molecules. In a classical adaptive 
immunity, four signals (0-3) are required for optimal DC/TH activation and differentiation (see 
Chapter I, Review of Literature). Immature peripheral DCs recognize highly conserved PAMPs 
and DAMPs via different receptors such as the PRRs and RAGE receptor (signal-0) (Matzinger, 
1994; Sousa, 2004; Hou et al., 2008; Kagan, 2012). Once the DC engulfs foreign antigenic peptide, 
it starts a process of maturation with processing and presenting of this peptide on its own major 
histocompatibility complex class II (MHC class II) molecule. Here, maturing DCs exhibit changes 
in cytokines production profile with concurrence homing to T zone at the draining lymph nodes. 
At this point, the DC is with less phagocytic capacity and more presenting activity. At the T zone 
of the lymph node, naïve T cell receptor (TCR) engages processed peptide on cognate MHC class 
II molecule on the DC (signal-1). This engagement activates T cell and render it expressing CD40L 
transiently with other costimulatory molecules and cytokines. The crosslinking of these 
costimulatory molecules on both cells represents signal-2. This will lead to downstream cell 
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signaling in both DCs and T cells. Cytokines from the DC such interleukin (IL)-1 family and IL-
2 serve as signal-3 for the T cells differentiation. Similarly, activated T cell produces cytokines 
that affect the same cell or neighboring cells such as IL-2 and IL-4. The type of the T cell cytokines 
depends on the type of the foreign peptide that was initially presented by the DC. The antigen-
specific signal-1 is necessarily inefficient to stimulate naïve T cell full differentiation into effector 
TH cells (subsets). T cell needs all the signals to complete proliferation and subsets differentiation 
such as TH1 or TH2 (Curtsinger et al., 1999; Erf, 2004; Corthay, 2006; Thaiss et al., 2011; Abbas 
et al., 2012). When B cells involved in antigen presentation, CD40-CD40L engagement is crucial 
event in T-cell-dependent B-cell activation and proliferation. CD40 participates in T-lymphocyte-
dependent antibody class switching, antibody affinity maturation, development of memory B cells 
and formation of the germinal centers (Noelle et al., 1992; Alvarez et al., 2008; Stavnezer, et al., 
2008; Elgueta, et al., 2009; Wu et al., 2010).  
Recent studies showed that the use of different agonists to CD40 leads to induction of adaptive 
immune response useful in cancer immunotherapy (Vonderheide and Glennie, 2013). CD40 
agonists revert the suppressive effect of tumor cells on macrophages, rendering them active 
antitumor phagocytes instead of tumor-promoting cells. CD40 agonists stimulate other APCs by 
triggering tumor-specific T cell immune response (Beatty et al., 2011; Palma and Lewis, 2013; 
Vonderheide et al., 2013). Anti-CD40 monoclonal antibodies (MAbs), soluble CD40L or viral-
vector expressing CD40L have shown to mimic humoral or cellular immune responses to a verity 
of T cell-dependent or independent immune responses (Dullforce et al., 1998; Hanyu et al., 2008; 
Thompson et al., 2015). 
In one approach, our group has recently shown that targeting chicken CD40 receptor for activation 
with anti-chicken CD40 MAb was extremely successful with robust immune responses against 
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haptens (Chen et al., 2010; Chen et al., 2012; Chou et al., 2016; Vuong et al., 2018). Anti-CD40 
MAbs showed several biological capacities such as agonistic or antagonistic effects. Anti-CD40 
agonistics are promising immunological adjuvants (Martin et al., 2017; Vuong et al., 2018). The 
limitation of using MAbs as vaccine adjuvants is the presence of the MAbs themselves due to their 
high immunogenicity that might interfere with the vaccine action, difficult and costly production 
(Chames et al., 2009).  
Therefore, the use of alternative, biologically accepted and low-immunogenic molecules, would 
be more beneficial for practical in vivo applications. Accordingly, we sought to utilize aptamers to 
substitute anti-chicken CD40 MAb. The folding pattern of single stranded oligonucleotides creates 
a molecular structure in which the ligand becomes incorporated. This phenomenon enables 
aptamers to have affinities and specificities to target molecules that may exceed those of MAbs to 
the same molecule. Many advantages of aptamers over MAbs; aptamers selection is via in vitro 
process. In addition, aptamers are thermostable, chemically resistant, reproducible and low 
immunogenic (Irvine et al., 1991; Hermann and Petel, 2000; Dollins et al., 2008; Baker, 2015; 
Bradbury, 2015; Jeddi and Saiz, 2017). 
In this study, we sought to stimulate chicken macrophage HD11 cell line by developing agonistic 
anti-chicken CD40 DNA aptamers. First, we developed anti-chicken CD40 extra domain DNA 
aptamer by systemic evolution of ligands by exponential enrichment (SELEX) procedure (Tuerk 
and Gold, 1990; Ellington and Szostak, 1990). Eight aptamer candidates reproduced in form of 
four rolling circle amplification (RCA) products (namely, RCAI –IV) (Ali et al., 2014; Lv et al., 
2015; Mohsen and Kool, 2016). RCA products exhibit thousands of tandemly repeated sequences 
of the selected aptamers to mimic the naturally occurring receptor-ligand oligomerization more 
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closely. We tested the RCA products on the HD11 cells line to record their stimulation via nitric 
oxide liberation by Griess assay (Crippen et al., 2003). 
Moreover, we specified the amino acid sequences crucial for receptor ligand interaction and 
receptor stimulation by limited proteolysis electrospray ionization liquid chromatography mass 
spectrometry (LC-ESI-MS) experiment. The pairing LC-ESI-MS with limited proteolysis studies 
to map the surface of proteins with unknown three-dimensional structures is becoming an 
invaluable technique (Sides et al., 2012). Using similar concept, we determined those sites that 
hindered to the enzyme of proteolysis and they can be detected by reduction in signal 
corresponding to the tryptic peptide associated with the site. 
 
2.2.MATERIALS AND METHODS 
2.2.1. Target protein, generation of recombinant extracellular domain of the chicken CD40.  
Our target protein was the chicken CD40 receptor; however, the recombinant protein used for the 
aptamers selection was chicken CD40 extracellular domain protein (chCD40ED). The protein was 
a kind gift from Dr. Luc R. Berghman at the University of Texas A&M. The recombinant 
chCD40ED protein was expressed in hybridomas, human embryonic kidney (HEK)-293 Freestyle 
cells in protein-free medium (Antagene Inc., Santa Clara, CA, USA) with concentration of 
1mg/ml. Briefly, total RNA was isolated from chicken spleen and cDNA was synthesized 
accordingly. The sequence encoding the chCD40ED, which was already determined, was 
amplified with nested PCR and the gene encoding the protein was cloned into expression vector 
pcDNA5 (Invitrogen) (Chen et al., 2010). 
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According to the mass-spectrometry analysis, the protein was with MW around 25712 Da (Figure 
2.5). The protein’s stock was diluted (w/v) with sterile 1X phosphate buffer saline (1XPBS) to 
concentration of 15μg/L and aliquoted into 1ml in sterile tubes and stored at –80°C. 
 2.2.2. Single stranded DNA library and primers  
A randomized ssDNA library, forward and reverse primers were all purchased from Integrated 
DNA Technologies, Inc. (IDT, Coralville, Iowa, USA). The oligonucleotide library design 
included flanking the variable region (40 nucleotides) with constant 20 nucleotides forward primer 
sequence at the upstream and constant 20 nucleotides reverse primer-binding site at the 
downstream. The randomized region of the library, which was with 40 nucleotides, was with 
theoretical diversity of 1X1024 random sequences (Table 2.1). The random region of the library 
designation based on equal incorporation of A, C, G and T bases at each position. The reverse 
primer was ordered as phosphorylated at the upstream to facilitate the action of the λ-exonuclease 
enzyme in the later step during the enrichment cycles. The ssDNA library and the primers were 
dissolved in sterile 1XTE buffer (Cat# T9285, Sigma-Aldrich), to 100μM according to the 
manufacturer and stored at -20ºC.   
2.2.3. In vitro aptamers selection procedure 
The procedure of aptamers selection was carried out using SELEX procedure as described 
elsewhere (Tuerk and Gold, 1990; Ellington and Szostak, 1990; Irvine et al., 1991). At the first 
round, 35μl of the ssDNA library (1μg/μl) equivalent to ~6 X 1014 units was diluted with 115μl 
binding buffer (50mM Tris HCl, 25mM NaCl, 5mM MgCl2, 10mM DTT (dithiothreitol), pH 7.5) 
(Wang et al., 2013). A denaturation process carried out by heating to the DNA library-in buffer to 
95°C for 10min. After, the mixture cooled down immediately to 4°C for 5min, and incubated at 
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room temperature (RT) for 10min. To exclude non-specific binders and filter-binders, the ssDNA 
library was passed three times through a 0.45μM nitrocellulose acetate membrane (HAWP, 
Millipore, MA, USA) using filter holder (“pop-top”, Millipore, MA, USA). The library and the 
target protein (50μl, 15μg/L) incubated together with rotation for 1hr at RT in the binding buffer. 
After the time passed, the library-protein mixture passed through the filter, and the filter washed 
3x with the binding buffer. The filter then immersed in 200μl of pre-heated (60ºC) elution buffer 
(0.4 M sodium acetate, 5mM EDTA, 7M urea; pH 5.5) for 5min. The eluted material was diluted 
with 200μl ddH2O and the DNA was precipitated with ethanol precipitation method (Wang et al., 
2013; Sypabekova et al., 2017). Each following SELEX enrichment round used only 75% of the 
volume of the target protein in the previous round while the protein concentration remained 
constant. 
2.2.4. PCR and dsDNA digestion into ssDNA 
After each enrichment cycle, the resulted dsDNA was digested into ssDNA with λ exonuclease 
enzyme (see below). The ssDNA was amplified with 25 PCR amplification cycles. The PCR was 
conducted using G2 Hot Start Green Master Mix (Cat# M7422, Promega). The 25μl reaction mix 
was 1μl (10μM) from the of the DNA library (enriched aptamers in the later cycles) as the template, 
2μl of each forward and phosphorylated reverse primers (4μM), and 12.5μl of 2X reaction buffer 
(pH 8.5). The reaction buffer composed of 2.5U of the polymerase enzyme, 400μM of each dNTPs 
and 4mM MgCl2. Nuclease-free water was added to adjust the final reaction volume to 25μl. The 
thermal cycles composed of 95°C for 5min as the denaturing step, followed by 25 thermal cycles 
composed of 95°C for 30sec, 56°C for 15sec and 72°C for 15sec. The final extension was at 72°C 
for 5min. The PCR products were monitored on 1% agarose gel stained with SYBR Safe dye 
(ThermoFisher Scientific, USA). The reverse primer was order as phosphorylated to facilitate this 
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task (Table 2.1). The PCR-resulted double-stranded DNA (dsDNA) was subjected to the action of 
λ exonuclease enzyme (Cat# M0262S, NEB, USA) to retain the ssDNA for the next round. The 
digestion reaction conditions were as recommended by the manufacturer.  
2.2.5. Cloning and sequencing 
2.2.5.1.Sanger sequencing  
As a process of monitoring, after six rounds of selection, the PCR products were cloned and 
sequences using Sanger sequencing method (Sanger et al., 1977). The cloning process utilized the 
pGEM-T and pGEM-T easy vector systems (Cat# A1360, Promega). As instructed by the 
manufacturer, the PCR product was inserted into the kit vector in ligation buffer. The insert-
containing plasmid DNA was transformed into electro-competent TOP10 E. coli (Invitrogen, 
Carlsbad, CA, USA) by pulsed high voltage electroporation (1750V for 5 milliseconds) (ECMTM 
830 electroporation generator, Fisher Scientific). After the transformation, 500μL of SOC media 
(Invitrogen, Carlsbad, CA) was added immediately and the bacteria was incubated for 2hrs at 37°C 
with shaking. The SOC medium-containing bacteria was streaked on Luria-Bertani (LB) medium 
supplemented with ampicillin (100μl/plate) (Cat # R110846, Thermo Fisher Scientific), IPTG 
(Calibiochem) (Cat # 420291, Sigma-Aldrich), and 5-bromo-4-chloro-3-indolyl-β-D-galactoside 
(X-Gal) (Cat # B1690, Thermo Fisher Scientific). After overnight incubation, the culture was 
screened and 15 white colony candidates were harvested. The identification of positively cloned 
colonies depends on the color differentiation. Bacteria do not harbor the pUC18 plasmid will be 
killed by the ampicillin. Whereas, bacteria do not carry the insert will appear in blue color colonies 
because of the X-Gal, and the bacteria that harbor the insert will appear in white colonies. One 
extra blue bacterial colony was included as a positive control for the assay. Those chosen colonies 
were lysed and the DNA was purified using QIAprep Miniprep kit (Giagen, Hilden, Germany) and 
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sent for Sanger sequencing (Eurofins MWG Operon, Louisville, KY, USA). Results were analyzed 
with ClustalW2 2.1 software (University College Dublin) (Singh and Bhatia, 2016) 
2.2.5.2.Illumina sequencing 
The procedure of high throughput Illumina sequencing was as described elsewhere (Schütze et al., 
2011; Scoville et al., 2017). The results were analyzed using “Galaxy Bioinformatics” (open 
source), and FastQC Version: 0.11.5 (Babraham Bioinformatics,  Babraham Institute, UK) (Thiel 
and Giangrande, 2016; Thiel, 2016; Randrianjatovo-Gbalou et al., 2018).  
Briefly, enriched aptamer samples from rounds 1, 2, 6, 8 and 10 were prepared for Illumina 
sequencing platforms. Each selected round’s ssDNA was barcode-tagged and used as a template 
for PCR amplification using Illumina sequencing primers (Table 2.1). The ssDNA were diluted 
with nuclease free water to have concentration of 10uM, then, the primers, which were already 
included with unique barcodes representing each SELEX cycle, have been utilized to amplify the 
templates. Twenty-five PCR cycles have been applied using KOD hot start DNA polymerase and 
buffer (Cat # 71086-3, Sigma-Aldrich, CA, USA). Then, PCR products were mixed together in 
the same volume within each category. The mixed DNA samples were PAGE-purified using 4-20 
% polyacrylamide gel (Life Technologies, NY, USA). Then, these DNA samples were mixed 
together so that approximately the same quantity of DNA from each of six samples would be 
included in the final mixed sample, based on the measurement with Qubit 2.0 Fluorometer. Finally, 
20μl of the final mixed sample (50.4 ng/ul) was sent to Genomics Core Facility at the University 
of California at Riverside, USA for Illumina sequencing using MiSeq with 151 cycles in single-
end mode. 
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The total number of the reads by the Illumina sequencing were about ~16 million reads; however, 
about 5% of the total reads were neglected due to their improper length or quality. The rest of the 
reads were tracked according to their barcodes. After analyzing the results, the highly-yielded 
enriched aptamers were tested for the free energy change (ΔG[kcal.mole-1]) of the three 
dimensional structure using the OligoAnalyzer 3.1 Tool at Integrated DNA Technologies 
(available online by Integrated DNA Technologies (IDT) website), and the most reliable ones have 
been chosen to be tested by the next step. 
2.2.6. Dot-blot hybridization assay  
Dot-blot assay was applied to detect the affinity of the candidate aptamers to the target protein. 
The assay was as described elsewhere (Vivekananda and Kiel, 2006; Wang and Li, 2013). 
According to the Sanger sequencing and the Illumina sequencing results, the candidate aptamers 
were ordered as biotinylated at the upstream (IDT, Coralville, Iowa, USA). Immune-Blot PVDF 
membrane (0.2μm, Cat # 162-0174, Bio Rad laboratories, Ca.) cut into 8 strips of 6cm2 
(1cm2/treatment). Ten microliters (15μg/mL) of the target protein was dropped onto the center of 
five of the test squares. After drying, the stripes blocked with KPL blocking buffer for 30min and 
washed for three times with 1X KPL washing buffer (Cat # 50-63-00, KPL, Gaithersburg, MD). 
Concentrations of (12, 25 and 50) μM of the aptamers (10μl each) were dropped onto the center 
of the test squares on the membranes. The membranes sat to air dry and washed (3X) with 1X KPL 
washing buffer.  Streptavidin-conjugated alkaline phosphatase (Cat # 475-300, KPL, Gaithersburg, 
MD) (diluted 1:500) poured on the membrane for 30min and another course of washing followed. 
Finally, the color developed by adding 5-bromo-4-chloro-3-indoxyl-phosphate and nitro blue 
tetrazolium (BCIP/NBT) substrate (Cat # 50-81-07, KPL, Gaithersburg, MD, USA). The reaction 
stopped by pouring tap water thoroughly. 
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2.2.7. Rolling circle amplification 
According to the dot-blot assay results, the enriched aptamers were with good affinity to the target 
protein, yet, their ability to sustain the clustering and oligomerization of the CD40 receptor in 
chicken HD11 macrophage cell line was questionable. To achieve the highest possibility for this 
process, RCA technique was suggested. Multivalent RCA products-containing polyvalent 
aptamers were acquired via aptamers-based template design (Ali et al., 2014). All the eight 
candidate aptamers were grouped into four groups with two aptamers each to design four 
complementary templates for RCA technique (Tables 2.1 and 2.3, Figure 2.1). The upstream end 
of all RCA templates was phosphorylated to sustain enzymatic ligation. The primer designation as 
20 nucleotides length complementary sequence to the upstream and the downstream extremities 
of the template together to assist the ligation (Table 2.1). Finally, a spacer complementary 
sequence (SCS) annealed thermally to ensure rigid regions among the repetitive aptamers 
sequences. The procedure of the RCA started with annealing 15-20pmol of the primer (equivalent 
up to 132ng/μl) with primer binding site on the template (1-2pmol equivalent to 129ng/μl) making 
the template as a circle with the aid of the primer, despite the template was still being nicked right 
in the middle of the primer. The primer-template mixture was heated first to 95°C for 10min, to 
56°C for 5min and then cooled down to RT in 50μL TE buffer. To ligate the nicked template, the 
ligation of the template with T4 DNA ligase enzyme (Cat# M0202S, NEB, USA) followed the 
annealing procedure. The ligation reaction conditions were as recommended by the manufacturer. 
For the polymerization, ɸ 29 DNA polymerase enzyme (Cat# M0269L, NEB, USA) was used. All 
the reaction conditions were as recommended by the manufacturer, except that the reaction was 
hold for 16hr at 30°C and then heat-inactivated at 65°C for 10min.  After each enzymatic treatment, 
the DNA was purified by ethanol precipitation method. For SCS adding, the RCA products quality 
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and quantity were evaluated using microplate reader (BioTeck). Two molecular weights of the SCS 
were mixed with one molecular weight of the RCA products. Again, the RCA products-SCS 
mixture was hold on heating for 10min at 95°C and for 50°C for 5min and then ice-cooled 
immediately to apply the annealing status.  
2.2.8. Measuring activation of chicken HD11 macrophage cell line 
Chicken HD11 macrophage cell line (Crippen et al., 2003) was propagated on 96-well plate at 
37ºC in a humidified atmosphere having 5% CO2 in Dulbecco’s modification of eagle’s medium 
(DMEM) (Mediatech, Manassas, VA) enriched with 8% fetal bovine serum (Atlanta Biologicals, 
Lawrenceville, GA) and 5% chicken serum (Sigma, St. Louis, MO). All treatments were applied 
when the confluence of the batch was 80% (Hussein and Qureshi, 1997; Crippen et al., 2003). 
After the treatment, the plate was incubated at the same conditions for extra four hours. When the 
time passed, the contents of every well was collected, centrifuged and the supernatant was 
subjected to Griess assay to detect the nitric oxide liberation in the medium. All cell line work was 
done in Dr. Berghman’s laboratory, University of Texas A&M. 
2.2.9. MALDI-TOF-MS, LC-ESI-MS/MS, and LC-ESI-MS   
For these experiments, we used SEQ1 and SEQ2 as the candidate aptamers individually or in 
combination because they showed best stimulation pattern on tissue culture experiment in form of 
RCA I. First, both protein and the individual aptamers were subjected to matrix-assisted laser 
desorption ionization time of flight mass spectrometry (MALDI-TOF-MS) using Bruker 
Daltonics, MALDI relex III time of flight instrument to confirm the expected molecular weight 
for both protein and the aptamers. The second experiment tested the identity of the target protein. 
The protein (1μg) was subjected to full digestion with trypsin (20ng) (Promega) in 25mM 
59 
NH4HCO3 ~ 7.5 pH buffer at 37°C for 1hr. Following, liquid chromatography electrospray 
ionization tandem mass spectrometry (LC-ESI-MS/MS), using Agilent Bruker Daltonics Amazon-
SL, used to confirm the protein identity as the CD40 receptor from Gallus gallus as using standard 
method described in elsewhere (Kannan et al., 2007).  
Last experiment was designed to understand aptamers-protein binding process properly. We 
conducted a limited proteolysis liquid chromatography electrospray ionization mass spectrometry 
(LC-ESI-MS) experiment. The LC-ESI-MS experiment has been done using Bruker ESQUIR-LC 
quadrupole ion trap (QIT) without MS/MS and intensities of the extracted ion chromatograms 
corresponding each tryptic peptide, which were used to determine the relative inhibition for the 
enzyme activity toward the chCD40ED protein due to aptamers binding. LC-ESI-MS was operated 
using standard method protocols described elsewhere (Kannan et al., 2007; Kannan et al., 2009). 
One microgram of the chCD40ED protein was subjected to the digestion with 20ng of trypsin 
(Promega) containing 25mM NH4HCO3 ~ 7.5 pH buffer at 37°C for 1h with and without the 
candidate aptamers (individually or in combination). In addition, negative control ssDNA aptamers 
random sequence was included. After the incubation period passed, the enzyme action was 
chemically inactivated by adding 5% FA in 60% acetonitrile (ACN) and the resulted digest was 
subjected to LC-ESI-MS. 
2.2.10. Statistical analyses 
Data from nitric oxide liberation are presented as mean ± standard error. Treatments with RCA 
products were in triplicates. Multi-Way Analysis of Variance (ANOVA) followed by Tukey’s 
honest significant difference (HSD) post hoc test were used to compare means of nitric oxide 
liberation among treatments to detect significance differences between and among several 
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treatments with RCA products on tissue culture with JMP Pro software (version 13, SAS Institute 
Inc., NC, free version by University of Arkansas). The p-values are reported as significant at 
p<0.001.  
 
2.3.RESULTS AND DISCUSSION 
2.3.1. In vitro selection, identification and characterization of the aptamers 
The naturally occurring CD40/CD40L interaction is a central event in orchestrating both branches 
of any given acquired immune response. In a recent study, our group established a novel anti-
chCD40 MAb. This well-characterized MAb showed the ability to induce significant stimulation 
in chicken HD11 macrophage cell line. When this MAb administered with different routes in 
combination with a desired peptide, the CD40-targeted immunogen induces robust immune 
response and several desired effects such as immunoglobulin class switching occur (Chen et al., 
2010; Chen et al., 2012; Chou et al., 2016). However, like all MAbs, the anti-chCD40 MAb 
production would make it impractical to commercialize this as vaccine adjuvant due to high cost 
and intense labor. To avoid these undesirable side effect and cost, we investigated the ability of in 
vitro-selected DNA aptamers to mimic the same effect as in MAb as agonist to the CD40 receptor 
on the same cell line. 
The SELEX procedure that applied for selection aptamers against chCD40ED started with random 
ssDNA library and continued as repetitive 10 enrichment cycles of SELEX as described by Tuerk 
and Gold (1990). Following each enrichment cycle, PCR procedure was carried out using the 
resulted aptamers as the template to amplify the enriched aptamers for the next round. PCR is 
useful tool to increase the yield and the purity of the enriched aptamers. To resume the SELEX 
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process, the amplified dsDNA was then being digested with λ-exonuclease. To avoid losing 
aptamers with high affinity to the target protein, the molar ratio of the protein to ssDNA library 
was shifted toward protein. The protein amount was reduced by 25% in every next round with the 
same concentration to apply selection pressure toward aptamers specificity (Berens et al., 2001).  
To evaluate the selection process, ssDNA products form round six was clonally sequenced with 
Sanger sequencing method (Sanger et al., 1977). The data obtained were analyzed using 
ClustalW2 2.1 software (University Collge Dublin) (Singh and Bhatia, 2016). The result showed 
that there were two identical aptamers sequences and a third sequence with considerable consensus 
among the others. One aptamer sequence was repeated two times over the 15 samples and the other 
was with 60% consensus sequence with these two sequences (Figure 2.1). These three aptamers 
sequences were evaluated by IDT OligoAnalayzer 3.1 tool software (available online by Integrated 
DNA Technologies (IDT) website, IDT, USA) to judge their fitness. The two different sequences 
were ordered as biotinylated DNA sequence at their 5’ prime end (IDT, USA) to apply dot-blot 
assay. The highly enriched aptamers may not be always suitable for the receptor stimulation. As 
stated by Yu et al. (2018), only those MAbs who are able to bind the receptor at certain sites will 
promote agonistic activities despite of high binding affinity (Figure 2.9D).  
In the next step, the ssDNA aptamers from rounds 1, 2, 6, 8 and 10 were sequenced using high 
throughput Illumina sequencing method. According to the barcodes we included for each round, 
there were around 4X106 reads/barcode from each round. Significantly, about 95% of the row 
reads were retained as high quality aptamers sequences when filtered with the bioinformatics tools. 
Analyzing the results with Galaxy bioinformatics and FastQC showed increasing in the selected 
aptamers enrichment over rounds (Thiel and Giangrande, 2016; Thiel, 2016; Randrianjatovo-
Gbalou, 2018). The analyzed data showed that there were highly enriched six sequences (SEQ1-
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SEQ6) over the aptamers pool (Table 2.2, Figure 2.2). When blotting these abundant six sequences 
against each selection round, the highest represent sequences proportion were (SEQ6 and SEQ5) 
consistently. To achieve calculations, round 1 considered to be the base line or round 0 as all the 
possible sequences are represented theoretically in the pool. When measuring the proportion of the 
enriched sequences/round and relative frequency, the six sequences were variable in enrichment. 
SEQ3 and SEQ5 were with the highest relative frequency observance, both steadily enriched over 
the SELEX cycles (Table 2.2). 
Depending on the results from Sanger sequencing and Illumina sequencing, eight candidate 
aptamers sequences assessed (two sequences form Sangers and six sequences from Illumina, Table 
2.3). Dot-blot assay evaluated the ability of the eight candidate aptamers to attach the target protein 
in vitro. Candidate aptamers were ordered as biotinylated at the upstream to evaluate their ability 
to interact with the protein on Immune-Blot PVDF membrane. The results showed that all aptamers 
candidate sequences were with significant binding affinity to the target protein at concentration of 
25μM or more (Figure 2.3). All the eight aptamers were able to detect the target protein with this 
assay and the detection limit was (15:10-50)μM protein : aptamers. It is convenient to refer that 
the candidate aptamers were with the primers and primer binding sites sequences when applied 
this assay due to the possibility that these sites might share in protein interaction as well. 
2.3.2. Rolling circle amplification 
As stated earlier, due to the smaller size of our aptamers candidates in comparison to the target 
receptor (the MW of each individual candidate aptamer is estimated to be around 24kDs whereas, 
the MW of the chicken CD40 receptor extra domain trimer is around 75kDa – Figure 2.7), RCA 
technique was suggested (Figure 2.4). RCA products would increase the chance of the CD40 
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receptor activation on the chicken macrophage cell line by spanning wider area on the receptor 
and by increasing the overall affinity of the ligand(s). To achieve this task, the complimentary of 
the eight candidate aptamers sequences were dual designed as templates for RCA procedure. RCA 
technique gives long tandem repetitive sequences (several hundreds) of the original template. 
Herein, RCA products make benefit of this feature and to increase the ability of the aptamers-
CD40 receptor clustering. The RCA products were polyvalent and multivalent products. Over the 
run of the RCA procedure, the RCA products were with high molecular weight (more than 10K 
nucleotides) (Figure 2.5). The ssDNA aptamers sequences within each RCA product were 
separated by short SCS representing dsDNA to apply rigid and inert stretches within the ssDNA 
of the RCA products long tail. This RCA products-SCS complex hybridization was to exclude any 
possibility of non-specific cell line activation by RCA products. Experimentally, each RCA 
products is with tandem repeats of the two included aptamers candidates and, each neighboring 
aptamers are separated by spacer-SCS; in other words, the RCA products is a repeated sequence 
of ssDNA (aptamers) and dsDNA of spacer-SCS, reciprocally. Here, the spacer-SCS stretches 
provide stability over the structure and to act as hinge region as in antibody. Additionally, we 
noticed that using any random RCA products with no spacer-SCS added could stimulate the nitric 
oxide liberation from the chicken macrophage cell line (data not shown).  Furthermore, adding the 
SCS has prevented the clumping and precipitation of the RCA products.   
The RCA procedure passes through several enzymatic treatments in exchange with DNA 
precipitation and purification procedures. Therein, the confirmation we had on the RCA products 
configuration and RCA products-SCS annealing was the digestion with restriction enzyme (AgeI). 
The SCS was included with restriction sequence. The digestion pattern of the RCA products with 
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this enzyme showed that we actually had the correct product and correct RCA products-SCS 
hybridization, thus, there was no need for the sequencing at this step (Figure 2.6, Table–2.1).  
2.3.3. Nitric oxide liberation and Griess assay.  
The RCA products-SCS complex were used to treat the chicken HD11 macrophage cell line 
(Crippen et al., 2003). The four aptamers-dependent templates were amplified into four RCA 
products namely RCA I to RCA IV.  
The results of Griess assay showed that there were detectable elevation in nitric oxide liberation 
in the media after the incubation with the RCA products for all sequences. However, there was 
significant variability in the efficacy and potency among RCA products. RCA I was with the 
highest response. The steep of the slope response was dose-dependent and significantly appeared 
in RCA I. Of course, the results were compared with negative control RCA products (NC-RCA); 
which are RCA products that had been designed by having two DNA sequences that have not been 
enriched according to the Illumina sequencing results to develop RCA template as in positively 
selected aptamers. The results were also compared with anti-chicken CD40 MAb that is known to 
stimulate the chicken HD11 cells as the positive control (Chou et al., 2016).  
The activity and viability of the chicken HD11 cell was also measured by adding 
lipopolysaccharide (LPS) as the general positive controls for this assay. All the RCA products 
induced a detectable liberation of the nitric oxide in the media with marked peak elevation with 
RCA I (Figure 2.9A). The stimulation of chicken macrophage HD11 cells with RCA I was with 
the highest nitric oxide liberation values at all concentrations and comparable with that of the anti-
chicken CD40 MAb (Figure 2.9B) (Hussein and Qureshi, 1997; Brightbill and Modlin, 2000; 
Crippen et al., 2003; Sun et al., 2003). 
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The results also confirmed that the highly expressed aptamers were not the ideal aptamers for 
receptor stimulation. Indeed, there are specific site(s) where ligand could only promote clustering 
and oligomerization of receptor (Yu et al., 2018). There are several anti- CD40 MAb, yet only 
those who interact with cysteine-rich region apically can promote receptor oligomerization. 
2.3.4. MALDI-TOF-MS, LC-ESI-MS/MS, and LC-ESI-MS 
The rationale behind using MALDI-TOF MS experiment was to verify the identity of the chCD40ED 
protein (Bonk and Humeny, 2001). The results of this experiment showed that the MW of this protein 
was 25712 Dalton (Figure 2.7). Another LC-ESI-MS/MS experiment was used to discover the 
binding sites of CD40 partially protected by DNA (Figure 2.10) (Sundqvist et al., 2007). For this 
experiment, we used SEQ1 and SEQ2 as these sequences represented by RCA I and gave best 
stimulation on tissue culture. Intensities of the tryptic peptides involving the detection the site(s) 
where these two aptamers attach to the target protein were low in comparison to the control chCD40ED 
protein without the aptamers. These complemented results showed that there where physical linking 
between the target protein and the aptamers at least at three different peptide segments, and, this 
configuration was strong enough to protect the protein from the action of the trypsin enzyme after the 
period of digestion. Each peak indicted the protected sequence within the protein by the action of the 
aptamers separately or reciprocally. Similar to previous cell line experiment where the NC-RCA was 
able to stimulate mild nitric oxide liberation (Figure 2.9), the negative control aptamers showed 
detectable protection activity against the action of trypsin enzyme too. Still, the two positive control 
aptamers are more consistent with their protection level. Moreover, to determine the sites where the 
aptamers attract the target protein, the data from the LC-ESI-MS were subjected to virtual protein 
tertiary structure configuration analysis (PyMOL, free software at: www.pymol.org). According to 
this software, the two aptamers are attaching the target protein at the amine terminate (Figure 2.11B) 
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and the addition of the two aptamers together acted synergistically. However, the actual sites where 
each aptamers links the protein did not investigated at this point. In the process of building the tertiary 
structure of our target protein, significant amino acid sequences participated in attraction the aptamers 
sequences. The fact that this region is flabby, herein, highly resonant and cannot be detected easily 
by many 3D protein-building software. It is suitable to demonstrate that in the actual CD40-CD40L 
interaction, the ligand is spanning the inner of the receptor pulling it inward. This receptor-ligand 
clustering causes the oligomerization of the receptor (Figure 2.11D) (Reyes-Moreno et al., 2004; 
Elgueta et al., 2009), whereas, in our receptor-aptamers clustering model, the aptamers link the 
receptor apically (tandem repeats of the RCA products). The CD40 receptor is a trimer, herein, 
clustering at the proximal extremities of the receptor trimer is what may cause the same effect as in 
receptor-ligand clustering and oligomerization (Figure 2.11C). 
 
2.4.CONCLUSIONS 
Recently, developing aptamers for variety of molecules has become well-established technology. 
Aptamers and aptamers-based molecules are to replace the traditional MAbs in molecular biology. 
Indeed, expansion in this field is yet to overcome the limitations of the use of the aptamers due to 
poorly understood molecular properties of these molecules. We proved that the DNA aptamers-
based RCA products are ideally capable of conducting the activation of chicken macrophage HD11 
cell line via the CD40 receptor. In this study, we report the first description of using ssDNA 
aptamers-dependent RCA products as an agonist for the chicken CD40 receptor. The polyduplex 
synthetic aptamers in the RCA products mimics the naturally occurring receptor/ligand interaction 
and subsequent receptor oligomerization. We also utilized the use of the DNA aptamers to halt the 
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action of the trypsin enzyme on the target protein by utilizing LC-ESI-MS experiment. Herein, we 
determined the actual site where our aptamers attach the protein. We confirmed the cell line results 
by showing three amino acid stretches at the amine site of the protein where the aptamers (or the 
RCA products) attach. Despite using monomer instead of the receptor trimer as our target protein 
for aptamers selection, yet, our protein was expressed in eukaryotic cell line system, which should 
support the post-translation modification. In naturally occurring CD40-CD40L interaction 
stoichiometry, upon initial physical contact of the ligand with its cognate receptor, the receptor 
undergoes clustering at the extracellular domain, thus, signal transduction occurs through the 
cytoplasmic domain (Grassme et al., 2002). The receptor’s extracellular crosslinking is what leads 
to receptor oligomerization and this observation was recorded with the natural and artificial 
agonists of the CD40; i.e., CD40L and anti-CD40 MAbs (Bjorck et al., 1994). The ligand has to 
configure with the receptor in a specific manner to induce the response (Figure 2.11). Interestingly, 
soluble CD40L was not able to induce the expected receptor signaling nor many anti-chicken 
CD40 MAbs. The conclusion was that there is a certain pattern and site for the ligand to act as an 
agonist (Baccam and Bishop, 1999; An et al., 2011). Our aptamers did not show any agonistic 
activity when administered to the macrophage cell line as an individual nor combined aptamers. 
The macrophage stimulation only occurred with RCA products. Similarly, we have proven that 
not all the aptamers we have selected were able to oligomerize the receptor significantly; only 
those who were able to link specific receptor sites were the successful. However, we did not 
investigate nor report any antagonistic activity of the studied RCA products (Cerchia et al., 2012; 
Soldevilla et al., 2016).  
Our goal is to create synthetic molecule could be preferably beneficial when loaded with 
appropriate antigen to act as specifically designed and sophisticated adjuvant. The flexibility we 
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provide with the use of aptamers-based RCA products makes it easier to introduce the aptamers 
into the biological systems without any molecular concerns. Indeed, the RCA products are 
naturally protected against any nuclease enzyme activity at the downstream due to the attached 
circular template (data not shown) and the intentionally biotinylated at upstream end to upload 
appropriate antigen.   
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2.5.TABLES 
Table 2.1. DNA Library, primers, RCA templates and spacer complementary sequences 
designs. The random library, which is with theoretical 1X1024 unique sequences, flanked with 
forward primer sequence at the upstream and with the reveres primer-binding site at the 
downstream. Phosphorylated reverse primer ordered to facilitate exonuclease activity. Illumina 
primers were included with barcodes at the upstream to split the sequences after NGS. RCA 
templates phosphorylated at upstream to apply enzymatic ligation. 
Description DNA Sequence 
Library CCG AAT TCG AAG GAC AAG AG (N)
40
† TCT TT TAT GCT ACG TCC 
CGC 
Forward primer (FP) CCG AAT TCG AAG GAC AAG AG 
Reverse primer (RP) Phosph/GCG GGA CGT AGC ATA AAA GA 
Illumina FP AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC 
GAC GCT CTT CCG ATC TNN NNN GG(BC)‡TT– (Library FP) 
Illumina RP (Library RP)–TAG AGC ATA CGG CAG AAG ACG AAC 
RCA-I template GCA TCT GAA C GCG GGA CGT AGC ATA AAA GAC GAA TTC ACT 
GCT CCA TTT ACA CCC CAT TAC CAA TTC CAC CTC TTG TCC TTC 
GAA TTC GG GAT CCA CCG GTA GCA GCG GGA CGT AGC ATA AAA 
GAC CTA GCC CTG CTC TTC TGA TCC CTA TTC CAT GTA GCC CTA 
CTC TTG TCC TTC GAA TTC GG GGA ACG TCT T* 
RCA-II template GCA TCT GAA C GCG GGA CGT AGC ATA AAA GAG CGG GAC GTA 
GCA TAA AAG AAA ACC CAA ACT GCA CTT ACT CTT GTC CTT CGA 
ATT CGG GAT CCA CCG GTA GCA GCG GGA CGT AGC ATA AAA GAG 
AAC AAT CGG AAC TGG TCA TCC TAG GAC GTC GTG ACT TAC CTC 
TTG TCC TTC GAA TTC GG GGA ACG TCT T 
RCA-III template GCA TCT GAA C GCG GGA CGT AGC ATA AAA GAG AGA TGA CCA 
ACC ATA CTG ACT TGA CAG CAT CCC TCA TCT CTC TTG TCC TTC 
GAA TTC GG GAT CCA CCG GTA GCA GCG GGA CGT AGC ATA AAA 
GAA TGG GGG TAG TTG CAA AGG ATA GGG GTA AAA GAA ATG TTG 
CTC TTG TCC TTC GAA TTC GG GGA ACG TCT T 
RCA-IV template GCA TCT GAA C GCG GGA CGT AGC ATA AAA GAT GAG TCG TGC 
TAC CGT TCT GTC CTA ATA CTC GTT TGT CTG CTC TTG TCC TTC 
GAA TTC GG GAT CCA CCG GTA GCA GCG GGA CGT AGC ATA AAA 
GAG GAC TCG ACA CGC CGG TCT GTC CTG GGA TTC GTT TTT TCT 
CTC TTG TCC TTC GAA TTC GG GGA ACG TCT T 
RCA-NC template GCA TCT GAA C ATG GGC AGT TCA AAC TAC GAC ATA GCA GAC 
CAA GGT ATA G GAT CCA CCG GTA GCA TGA TGC AGG TCC TGT 
AAT TGG ACT GAT CAC ATA CCT AGA T GGA ACG TCT T 
RCA primer GTT CAG ATG CAA GAC GTT CC 
Spacer-complement  GAT CCA CCG GTA GCA 
† Represents random sequence  
‡ Represents barcode sequence 
*Single underline represents the primer-binding site and the double underline represents the 
spacer complementary sequence 
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Table 2.2. Aptamers proportion and relative frequency at each enrichment SELEX round. 
Sequences of each rounds marked with certain barcode to ensure accurate splitting with the proper 
software. The proportion of six highly enriched aptamer sequence/round and their relative 
frequency upon each round have been estimated.  
Round Barcode 
No. of 
Sequences/round 
Sequence 
% of enriched 
seq./round 
Relative frequency 
1 TAGATCGC 4.438 X106 
SEQ1 0.00006 0.028 
SEQ2 0.00011 0.0467 
SEQ3 0.00155 0.6449 
SEQ4 0.00048 0.1962 
SEQ5 0.00018 0.075 
SEQ6 0.00002 0.0095 
   SEQ1 0.00231 0.0945 
   SEQ2 0.00198 0.0809 
2 CTCTCTAT 3.9 X106 SEQ3 0.01408 0.5766 
   SEQ4 0.00408 0.167 
   SEQ5 0.00139 0.0568 
   SEQ6 0.00059 0.0243 
6 TATCCTCT 4.368 X106 
SEQ1 0.00104 0.0442 
SEQ2 0.00133 0.0569 
SEQ3 0.00319 0.1364 
SEQ4 0.00591 0.2531 
SEQ5 0.00053 0.0226 
SEQ6 0.01136 0.4867 
8 AGAGTAGA 4.038 X106 
SEQ1 0.02725 0.053 
SEQ2 0.07678 0.1489 
SEQ3 0.21052 0.4083 
SEQ4 0.05697 0.1104 
SEQ5 0.04211 0.0817 
SEQ6 0.10194 0.1977 
10 ACTGCATA 2.739 X106 
SEQ1 0.16631 0.0529 
SEQ2 0.31121 0.0652 
SEQ3 3.20593 0.6712 
SEQ4 0.66189 0.1385 
SEQ5 0.17813 0.0374 
   SEQ6 0.16631 0.0349 
Relative frequency calculations: Summation of the count of each enriched sequence per round 
(SEQ1+ SEQ2+…+ SEQ6) = SEQtotal, and divided each enriched sequence count by the SEQtotal 
= (SEQ1/ SEQtotal, SEQ2/ SEQtotal,…, SEQ6/ SEQtotal)  
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Table 2.3. Candidate aptamers. Eight highly enriched aptamers sequences from Sanger 
sequencing and Illumina sequencing were used to design four RCA templates. Each template, 
which composed of primer binding site, spacer and two aptamers sequences, enzymatically 
circularized with the aid of the primer.  
Description Aptamers RCA combination 
SEQ1 
(Illumina) 
CCG AAT TCG AAG GAC AAG AGG TGG AAT TGG TAA TGG 
GGT GTA AAT GGA GCA GTG AAT TCG TCT TTT ATG CTA 
CGT CCC GC 
RCA I 
SEQ2 
(Illumina) 
CCG AAT TCG AAG GAC AAG AGT AGG GCT ACA TGG AAT 
AGG GAT CAG AAG AGC AGG GCT AGG TCT TTT ATG CTA 
CGT CCC GC 
SEQ3 
(Illumina) 
CCG AAT TCG AAG GAC AAG AGT AAG TGC AGT TTG GGT 
TTT CTT TTA TGC TAC GTC CCG CTC TTT TAT GCT ACG 
TCC CGC 
RCA II 
SEQ4 
(Illumina) 
CCG AAT TCG AAG GAC AAG AGG TAA GTC ACG ACG TCC 
TAG GAT GAC CAG TTC CGA TTG TTC TCT TTT ATG CTA 
CGT CCC GC 
SEQ5 
(Illumina) 
CCG AAT TCG AAG GAC AAG AGA GAT GAG GGA TGC TGT 
CAA GTC AGT ATG GTT GGT CAT CTC TCT TTT ATG CTA 
CGT CCC GC 
RCA III 
SEQ6 
(Illumina) 
CCG AAT TCG AAG GAC AAG AGC AAC ATT TCT TTT ACC 
CCT ATC CTT TGC AAC TAC CCC CAT TCT TTT ATG CTA 
CGT CCC GC 
SEQ7 
(Sanger) 
CCG AAT TCG AAG GAC AAG AGC AGA CAA ACG AGT ATT 
AGG ACA GAA CGG TAG CAC GAC TCA TCT TTT ATG CTA 
CGT CCC GC 
RCA IV 
SEQ8 
(Sanger) 
CCG AAT TCG AAG GAC AAG AGA GAA AAA ACG AAT CCC 
AGG ACA GAC CGG CGT GTC GAG TCC TCT TTT ATG CTA 
CGT CCC GC  
*Each two aptamers sequences within the template separated by spacer complementary sequence 
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2.6.FIGURES 
 
Figure 2.1. Sanger sequencing results. Sequences of the aptamers identified after six rounds of 
SELEX selection against chCD40ED protein. The aligned sequences represent the variable regions 
only with no primer binding sites. 
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Figure 2.2. Illumina sequencing results. Normalized exponential increase of six highly enriched 
aptamer sequences among DNA pool over rounds of the enrichment cycles of SELEX. 
Normalization calculation [(frequency of aptamer sequence X 100/total number of reads)/(% the 
aptamer sequence in R1)]. R1 as the reference round (R0) since all sequences should be represented 
hypothetically.  
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Figure 2.3. Dot-blot assay results. Eight Immuno-Blot PVDF membrane stripes, each divided 
into 6cm2 activated with concentrated methanol and washed. 10μl of the chCD40ED protein 
(15μg/mL) dropped onto the center of (A, B, D-F), air dried and blocked with commercial blocking 
buffer. 20μl of each of eight biotinylated aptamers sequences (Table 3.3) dropped on the center of 
each stripe within (D-F) at concentrations 12, 25 and 50μM, respectively. 20μl biotinylated anti-
CD40 MAb positive control (10μg/mL) (A) and 1XIPBST (C) were the positive and the negative 
controls, respectively. The stripes set for 30min, washed (3x) and streptavidin-alkaline 
phosphatase was added followed by BCIP/NBT substrate.  
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Figure 2.4. Schematic illustration represents the process of ssDNA aptamers-based RCA. The 
candidate aptamers were dual configured in one template. Other constituents, such as primer 
binding site and spacer were included too. The products of the RCA are then annealed with spacer 
complementary sequence to sustain dsDNA between each two-neighbor aptamers, which in turn, 
sustains rigidity at this particular site. The two adjacent aptamers sequences would be flabby and 
the spacer-spacer complementary will be serve as the hinge region. 
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Figure 2.5: RCA products on denaturing 15%TBE urea gel. According to Illumina and Sanger 
sequencing, eight aptamers candidates were chosen to prepare four RCA templates (RCA I-IV, 
lanes 2-5, respectively).  First, the templates were annealed with single spanning primer. Then, the 
templates were ligated with T4 DNA ligase, and last, the primer-template was polymerized with 
ɸ29 DNA polymerase. The resulted RCA products were hybridized with spacer complementary to 
produce alternating repeat regions of ssDNA and dsDNA. This is to sustain the rigidity and to 
reduce aptamer-aptamer interaction configuration.  
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Figure 2.6. RCA products assessment after the digestion with AgeI restriction enzyme 
(loaded on 15% TBE urea denaturing gel). RCA products were prepared by the ligation of the 
linear ssDNA template with T4 DNA ligase (Cat# M0202S, NEB) with the presence of primer.  
After incubation with ɸ 29 DNA polymerase (Cat# M0269L, NEB), the resulting RCA products 
were digested with AgeI restriction enzyme according to manufacturer instructions (Cat# R0552S, 
NEB).  The templates were designed to produce products containing the spacer complementary to 
serve as a restriction site for this enzyme.  To prove successful incorporation of this spacer-AgeI 
region, the AgeI enzyme was incubated with RCA products in three types of buffers (NEBuffer 
1.1, NEBuffer 2.1 and NEBuffer 3.1 represented by AgeI-1, AgeI-2 and AgeI-3, respectively) to 
show cleavage of the RCA product  
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Figure 2.7. Identification of the MW of the CD40 receptor protein by mass spectrometry. 
SDS-PAGE gel loaded protein (1mg/mL) was sliced-cut and tested with MALDI-TOF-MS of the 
protein produced by trypsin digestion. The peak molecular weight of the protein is 25712 Dalton. 
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Figure 2.8. Schematic illustration represents the experimental design of LC-ESI-MS. LC-
ESI-MS was used to discover the binding sites of CD40 that were partially protected by DNA and 
to test the ability of the candidate aptamers to attach and protect the target protein from the action 
of trypsin enzyme. The enzyme was added after the incubation of the protein with the aptmaers-1 
(blue), aptamers-2 (green) separately or in combination. Of course, NC aptamers (black) was 
included in the process of testing the digestion. Mass-spectrometry assay and spectrum analysis 
were used to detect the undigested amino acid sequences.  
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Figure 2.9. Nitric oxide liberation from chicken HD11 macrophage cell line over increased 
concentrations of RCA products (A: RCA I to RCA IV in comparison with NC-RCA, B: RCA 
I in comparison with NC-RCA and anti-chCD40ED MAb). The RCA products were incubated 
overnight with the HD11 macrophage cell line in concentrations 1, 5, 10, 25, 50, 100, 200, 300 
and 350 (μg/ml) in triplicates. The nitric oxide liberated was measured using Griess assay and 
showed slop increasing in regard to dose applied. The result was compared to anti-chicken CD40 
MAb which is known to have the effect on this cell line (Chen et al., 2010) and negative control 
RCA (two aptamer candidates that were not enriched in the Illumina sequencing results). Multiple 
way ANOVA and Tukey’s honest significant difference (HSD) post hoc test were applied to detect 
significant differences within treatments. Different uppercase letters represent significant 
difference at p<0.0001. 
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Figure 2.10. LC-ESI-MS results. After incubation of recombinant chCD40ED protein (25712 D, 
gray line, gray circle) with the aptamers [SEQ1 (double line), SEQ2 (dished line, black triangle), 
SEQ1 and SEQ2 (black line, black circle), and NC-SEQ (dashed gray line)], the protein was 
subjected to trypsin digestion overnight. Three distinct regions on the protein sequence were 
protected from digestion (A, B and C). The peptide sequences were most effectively protected by 
the aptamers in combination.  
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Figure 2.11. Virtual tertiary structure of chCD40ED showing the potential aptamers linking 
sites.  A) Cartoon modeling shows the tertiary structure of the protein.  B) Space-filling model 
representing the virtual aptamers-protein interaction sites. Three regions (blue, yellow and orange) 
determined by MALD-TOF-MS experiment. The blue region represents long flabby peptide 
sequence where CD40L attaches. C) Top view of virtual trimer 3D structure of the chCD40ED 
(Mesh model, gray) with the potential aptamer linking sites (space filling model, blue, white and 
black). These sites located in the inner of the receptor resembling the actual ligand binding sites 
(see below). D) CD40-CD40L interaction (human) where the CD40 and the CD40L are 
incorporated. In addition, anti- CD40-MAb Fc interaction regions. With the receptor-MAb model, 
agonistic activity of the MAb increases proximally over the receptor, whereas, the antagonistic 
activity increases distally. 
Sources: A, B & C, PyMOL 2.2 software, W. L. DeLano, Schrodinger, Inc., D, cited: Yu, X. et 
al., 2018. Cancer Cell. 33, 664-675.    
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Figure 2.12. Alignment of one RCA I products unit. Hypothetically, this figure represents one 
unit of the RCA products showing the aligned three regions that are highly conserved between the 
two sequences (SEQ1 and SEQ2) (blue font). These regions might be essential in the aptamers-
protein interaction. The hairpin prediction done manually due to the presence of the spacer-spacer 
complementary region (blue trapezium), which is a dsDNA and we could not find software can 
predict the hairpin of the mixed ssDNA and dsDNA molecule.  
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ABSTRACT 
 
Cluster of differentiation 40 (CD40) receptor on antigen presenting cells, including B cell, 
engagement with CD40 ligand (CD40L/CD154) on activated T helper (TH) cell provides the 
ignition signal required for B cell proliferation, differentiation and antibody production. 
Subsequently, there would be upregulation of many required molecules during the path of acquired 
immune response. Previously, we developed DNA aptamers that were specifically selected against 
chicken CD40 receptor extracellular domain. We showed that these aptamers –in form of rolling 
circle amplification products (RCA-p) – were capable of induction stimulation in chicken 
macrophage HD11 cell line. Here, we sought to test the potential ability of these aptamers to 
enhance an acquired immune response to low immunogenic peptide hapten in vivo by actin as 
immunological adjuvant. We tested the ability of our aptamers to increase the efficacy of the 
immune response to this low-immunogenic peptide hapten by increasing IgG response in broiler 
chickens after the immunization with RCA-peptide immune complex. For this purpose, we 
prepared an immune complex composed of two biotinylated aptamers-based RCA products 
molecules conjugated with streptavidin, which in turn, conjugated with two biotinylated peptide 
molecules. We administered this immune complex to broiler chickens at two different doses 
(25μg/bird) or (50μg/bird) at age 7 and 21 days via subcutaneous route at the nape of the neck. 
The later immune response quantification of the anti-peptide IgG titer in the serum samples by 
ELISA showed that the RCA products-peptide immune complex at dose of 50μg/bird was able to 
induce robust immune response as early as 7 days post-immunization and the antibody titer 
remained high until the end of the experiment. On the other hand, immunization with the lower 
dose showed gradual increase in the antibody titer and needed a booster dose. The use of aptamers 
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as sophisticated immunological adjuvants gave promising results, and would lower the cost of 
vaccines and would change the strategy of vaccination programs. 
Key words: Broiler, DNA aptamers adjuvant, rolling circle amplification products, CD40. 
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3.1.INTRODUCTION 
Cluster of differentiation 40 (CD40) is a surface receptor glycoprotein that expressed on antigen 
presenting cells (APCs) and other non-immune cells. The ligand for this receptor is the CD40 
ligand (CD40L/CD154) which expressed by activated T helper (TH) lymphocyte transiently. This 
receptor is a member of tumor necrosis factor receptor superfamily, whereas the ligand is a member 
in tumor necrosis factor superfamily (Stout and Suttles, 1996; van Kooten and Banchereau, 1997; 
Bosson et al., 2006; Ma and Clark, 2009; Suttles and Stout, 2009). In essence, naïve T (TH/TH0) 
lymphocyte requires three constative signals for activation and differentiation. Signal-1 gained by 
T cell receptor (TCR) engagement with cognate major histocompatibility complex (MHC) class 
II/peptide on APCs, signal-2 provided by costimulatory molecules engagement on both cell types, 
and signal-3 comes from cytokines released by both activated cell types. When the third signal 
received, activated TH cell starts to differentiate into subsets of effector TH cell such as TH1 and 
TH2. The type of the T cell subset depends on the type of the foreign peptide, which in turn, guides 
the cytokine profile of both cell types. (Caux et al., 1994; Pinchuk et al., 1994; Sallusto and 
Lanzavecchia, 1994; Ma and Clark, 2009; Okoye and Wilson, 2011; Gerlach et al., 2012; Tubo 
and Jenkins, 2014). APCs, on the other hand, require signal-0 drown from chemokines for 
maturation and homing (Thaiss et al., 2011). The resulted immune response upon the engagement 
of the CD40 receptor with its ligand is different according to the type of the APC and the type of 
the foreign peptide. A well-studied pathway has demonstrated that TH cell causes DCs to promote 
CD8+ cytotoxic T lymphocyte (CTL) activation via CD40-CD40L pathway (Vonderheide and 
Glennie, 2013).  The three-cell type activation model requires that both TH and CTL cell receptors 
must engage cognate MHC class II or I co-expressed foreign antigens on the same DC. This triple 
cell engagement leads to DC activation, TH and CTL cells activation/differentiation. Schoenberger 
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et al. (1998), documented that priming DCs with agonistic anti-CD40 monoclonal antibody (MAb) 
could provide help for CTL in CD4-depleted mice. 
Macrophages produce IL-12 and receive activation from TH1 via CD40L and interferon-gamma 
(IFN-γ) in classical macrophage activation pathway. IFN-γ, which is a potent activator for 
macrophage, greatly enhances the activity of macrophages against the intracellular pathogens. 
Both CD40L and IFN-γ share synergetic effect on macrophages to facilitate their production of 
MHC class II molecule and several enzymes such as phagocyte oxidase and inducible nitric oxide 
synthase, which stimulate the production of reactive oxygen species and nitric oxide in the 
phagolysosomes, respectively. CD40L and IFN-γ are also enhance the production of lysosomal 
enzymes in the macrophages presenting peptide/MHC class II molecule to the TH cells. Similarly, 
in innate immune response, macrophages receive the same signal of activation by natural killer 
cells (Ma et al., 2003; Scott et al., 2004; Abbas et al., 2015). It has been shown that CD40 ligation 
in macrophages promoted a promising anti-cancer activity within these cells. Macrophages play 
role in stimulation of angiogenesis at the site of cancerous tissue, hence, promote cancer 
metastasis. In addition, macrophages suppress anti-cancer innate and adaptive immune response 
by suppressing NK and T cells (Noy and Pollard, 2014). Ligation of CD40 on these macrophages 
reverted their tumor-enhancing activity; and render them active antitumor participant cells. 
However, other studies showed that CD40 is expressed by the cancer cells themselves. Anti-CD40 
agonists such as MAb adjuvants induced antitumor activity by several mechanisms (Rakhmilevich 
et al., 2012). Controversially, CD40 ligation promotes anti-apoptosis in B cells while soluble 
CD40L and agonistic anti-CD40 MAb may promote apoptosis of certain CD40 expressing tumors 
without any participation of CD40 expressing immune cell (Eliopoulos et al., 2000, Vonderheide 
and Glennie, 2013).  
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Upon TCR-peptide/MHC class II engagement, immunological synapse (IS) forms. On the T 
lymphocyte side, TCR is the central molecule within this synapse, however, other costimulatory 
molecules participate considerably such as CD3 and CD28 and CD40L (Abbas et al., 2012). When 
B lymphocyte involved in formation of IS with TH, rapidly accumulated CD40L is last shortly 
(Yellin et al., 1994). The molecular mechanism of diminishing CD40L after the TH activation 
explained by several publications. Detection of soluble form of the CD40L in the media after T 
cell activation suggested the usefulness of this form for further activation of other uninvolved 
immune components (Graf et al., 1995). In a paradox, Hollenbaugh et al (1992) were able to induct 
costimulation, but not full activation, for B cells by the soluble form of the CD40L. Other 
publications suggested that after the CD40-CD40L engagement, the CD40L detached from the TH 
cells and endocytosed by the antigen-presenting B cell (Gardell and Parker, 2017). This 
phenomenon, which is antigen-dependent, is to sap activated TH cells render them recruiting 
bystander B cells.  The outcome of CD40-dependeant B cell activation with natural CD40L, 
soluble CD40L or agonistic anti-CD40 MAb resulted in B cell proliferation with increased MHC 
class II molecule expression and differentiation into plasma cells and memory cells. Plasma cells 
undergo profound production of antibody with high affinity maturation, and antibody isotype class 
switching. (Kawabe et al., 1994; Han et al, 1995; Kawabe et al., 2011; Gardell and Parker, 2017).  
Recent studies showed that the use of different agonists to CD40 receptor would lead to induction 
of acquired immune response. Agonists, such as anti-mouse CD40 monoclonal antibodies (MAbs) 
or soluble CD40L, were able to mimic the course of natural acquired immune response (Richman 
and Vonderheide, 2014a; Beatty et al., 2017). In one approach, our group had shown that the use 
of the chicken CD40 receptor, as the target for activation with anti-chicken CD40 MAb, was 
extremely successful with robust immune responses. (Chen et al., 2010; Chen et al., 2012). 
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Recently, we showed that DNA aptamers that had been specifically selected against chicken CD40 
receptor extracellular domain (chCD40ED) were capable of stimulation of chicken macrophage 
HD11 cell line (data unpublished). Thus, our DNA aptamers are one additional agonist to the CD40 
receptor. We aimed to substitute the anti-chicken CD40 MAb with DNA aptamers. Aptamers have 
many advantages over the monoclonal antibodies such as thermostability, chemical resistance, 
reproducibility, and low cost (Jayasena, 1999; Song et al., 2012).  
Anti-CD40 agonists could act as immunological adjuvants. We sought to test the ability of our 
anti-chCD40ED DNA aptamers (in form of rolling circle amplification products – RCA products) 
to act as immunological adjuvant in chicken. Herein, we might induce guided immune response 
toward peptide hapten in chickens with better potency and efficacy. For this purpose, the RCA 
products become chemically loaded with short low immunogenic peptide hapten with the aid of 
streptavidin. The peptide was a synthetic sequence of the external domain of matrix protein 2 
(M2e). This peptide is a short peptide that is unlikely to induct immune response by its own (Feng 
et al., 2006; Vuong et al., 2018). We administered the RCA products-M2e peptide immune 
complex to broiler chickens. Briefly, we conjugated two molecules of aptamers-based RCA 
products with streptavidin, which in turn, conjugated with two molecules of the peptide as the 
hapten. We administered this immune complex subcutaneously in two different doses according 
to the RCA products concentration (50μg/bird or 25μg/bird) to broiler chickens in priming and 
boosting doses at 7 and 21 days. In either RCA products dose, the peptide concentration was 
0.2μg/bird.  
The results showed that this immune complex could induce significant level of anti-peptide IgG 
antibody titer in the chicken sera as early as seven days post-immunization when 50μg/bird was 
administered. This antibody titer remained high significantly to the fourth week post-
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immunization. However, birds that had been immunized with the lower dose needed the boosting 
dose to sustain detectable level of the antibody titer at the end of the experiment. Our work would 
bring provide new foundations for peptide vaccine adjuvanted with aptamers-based adjuvants.  
 
3.2.MATRIALS AND METHODS 
3.2.1. Chickens, random mixing and management  
The conditions for animal use in this study were met the requirements of and approved by the 
Institutional Animal Care and Use Committee (IACUC) of the University of Arkansas (permit # 
18127, see appendix). Total 120 broiler one-day-old chicks were divided into six groups (n=20) bt 
different color tags in comingle pen. The chicks were Cobb-Vantress Off Sex – Male obtained on 
the day-of-hatch from the Fayetteville hatchery, Fayetteville, AR. The chicks were mechanically 
block randomized by moving 1/3 of each of the chicks from three boxes to a single new chick box, 
thus equally re-mixing each of the boxes. This was done in case boxes were derived from different 
hatchers and/or potentially different breeder sources (this variability has historically been the most 
critical for randomization effects). The management practice took the consideration of the broiler 
management guide of Cobb (cobb-ventress.com). 
3.2.2. Aptamers, rolling circle amplification products and M2e peptide 
3.2.2.1.Aptamers.  
Previously, we developed DNA aptamers targeting chicken CD40 extracellular domain 
(chCD40ED) protein in process of systemic evolution of ligands by exponential enrichment 
(SELEX) (Tuerk and Gold, 1991; Ellington, and Szostak, 1990) (unpublished data). Briefly, ten 
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rounds of enrichment via SELEX procedure needed to develop these DNA aptamers against the 
target protein. We run several assays to prove the affinity, the specificity and the biological activity 
of our aptamers toward this target protein in vitro. We successfully stimulated nitric oxide 
liberation from chicken macrophages HD11 cell line with our aptamers in form of RCA products. 
In addition, we specified the sites where our aptamers attached the target protein by running an 
LC-ESI-MS experiment (see Chapter II). 
3.2.2.2.Rolling circle amplification products.  
The anti-chCD40ED aptamers we developed were prepared in form of biotinylated RCA products. 
The biotinylation process achieved by hybridizing upstream-biotinylated primer with the template. 
Biotinylation of the RCA is to facilitate the conjugation with streptavidin in the later step.  The 
process of aptamer-dependent RCA products was as described elsewhere (Blanco et al., 1989; 
Johne et al., 2009). Briefly, our RCA technique relied on preparing RCA template depending on 
our DNA aptamers sequences. The template composed of two aptamer sequences separated by a 
spacer sequence. We circularized the template by annealing primer (20 nucleotides) that 
complementary to the upstream and the downstream of the ssDNA template and ligated of the 
nicked sequence between the primer and the template with T4 DNA ligase enzyme (Cat# M0202S, 
NEB, USA). The RCA template ordered as phosphorylated at the upstream (IDT, Coralville, Iowa, 
USA) to sustain the enzymatic ligation.  
The procedure of the RCA started with annealing 15-20pmol of the primer (equivalent up to 
132ng/μl) with primer binding site on the template (1-2pmol equivalent up to 129ng/μl). The 
primer-template mixture was heated first to 95°C for 10min, to 56°C for 5min and then cooled 
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down to RT in 50μL 1xTE buffer. To ligate the nicked template, the ligation of the template with 
T4 DNA ligase enzyme as recommended by the manufacturer (Ali et al., 2014). 
The polymerization of the template was with ɸ 29 DNA polymerase enzyme (Cat# M0269L, NEB, 
USA). All the reaction conditions were as recommended by the manufacturer except that the 
reaction was hold for 16hr at 30°C and then heat-inactivated at 65°C for 10min.  After each 
enzymatic treatment, the DNA was purified by ethanol precipitation. For SCS adding, two 
molecular weights of the SCS were mixed with one molecular weight of the RCA products. Again, 
the RCA products-SCS mixture was hold on heating for 10min at 95°C and for 50°C for 5min and 
then ice-cooled immediately to apply the annealing status. The RCA products represented tandem 
repeats of the original aptamers, hence; increase the chance for CD40 receptor activation in vivo. 
Adding SCS piece to ensure rigid sequences composed of double stranded DNA in exchange with 
our aptamer sequences to serve several purposes such as conserving the original DNA aptamers 
sequence by avoiding any form of dimerization and increasing the spanning area of our aptamers. 
3.2.2.3.Peptide immunogen.  
A commercial synthetic amino-terminus biotin labeled M2e peptide was a kind gift from Dr. Luc 
R. Berghman at the University of Texas A&M. The peptide was a biotinylated sequence 
(GenScript Inc. Piscataway, IL). This peptide, which was with the sequence 
“NAWSKEYARGFAKTGK”, representing the ectodomain of the matrix protein 2 of the influenza 
virus (Vuong et al., 2018). Conceptually, the biotinylation is to promote the conjugation of this 
peptide with streptavidin to form unit in the immune complex (see below).  
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3.2.3. Immunizing complex preparation, doses, timing and routes for administration 
Immunization complexes were prepared as described by Chen and co-workers (2012). Briefly, 
streptavidin (Thermo Fisher Scientific Inc., Rockford, IL) was used as the central molecule that 
conjugate other molecules in the immune complex (Figure 3.1). As mentioned above, the M2e 
peptide was ordered as biotinylated (GenScript Inc. Piscataway, IL), whereas the biotinylation of 
the RCA products was by ordering a biotinylated primer at the upstream to apply the RCA 
procedure. The biotinylated M2e peptide (0.2μg) was mixed with the biotinylated RCA products 
(50μg) in 1 to 1 ratio on molecular basis in 1xPBS with rotation at room temperature (RT) for 3hrs. 
The peptide-RCA products mixture then added to streptavidin in 2 to 1 ratio and stirred at 4°C for 
3hrs. Biotinylated anti-chCD40ED MAb was used as a control for our immune complex. This 
MAb was another kind gift from Dr. Luc R. Berghman at the University of Texas A&M. 
The same procedure was followed when preparing the anti-chCD40ED MAb-based immune 
complex, the M2e peptide alone, or the RCA products alone. Similarly, the peptide or the RCA 
products alone ratio to the streptavidin was 2 to 1.  
The immunizing doses and timing were as described in Table 3.1. The total volume of the 
calculated doses for either immunizing formula was 0.4mL/bird. The formulation of the 
immunizing complexes was in an emulsified PBS containing [5% (v/v) squalene, 0.4% (v/v) 
Tween 80 (Sigma-Aldrich, St. Louis, MO) in PBS]. 
3.2.4. Blood sampling 
Blood sampling was at weekly intervals in a sterile procedure. The blood were collected from the 
jugular vein at week 1 and from the brachial wing vein at the next four weeks. In the first week, 
102 
approximately 1 mL of blood was collected using 25G needles, 1 inch long in 5 ml syringes. In 
the next four collection procedures, 2-3 mL were collected using the same needle-syringe 
conformance. The blood samples were transferred to sterile and labeled tubes with lids. After blood 
complete clotting, blood samples were subjected to centrifugation for 5 min at 500xg and the sera 
were stored at -20°C (Lumeij, 1987; Kelly et al., 2013).  
3.2.5. Quantification of specific IgG by ELISA 
Antigen-capture ELISA was used to quantify the level of the anti-peptide IgG titer in the chicken 
sera. All serum samples were loaded in duplicates in a 96-well plate throughout the assay. The 
ELISA procedure started by incubation of the biotinylated M2e peptide (MW 2267.2Da) with 
5μg/mL goat anti-biotin antibody (MW 150kDa) (ThermoFisher Scientific Inc., Rockford, IL), in 
1 to 1 molecular ratio  in 10mL 0.05M carbonate-bicarbonate buffer (pH 9.6) for 2hrs at RT with 
rotation. 100μL of this peptide-antibody complex then coated a 96-well microtiter plate (MaxSorb, 
Thermo Fisher Scientific Inc., Rochester, NY) overnight at 4°C. Next, the un-adsorbed 
supernatants were removed and the plate was washed (3x) with 200μL 1xPBS-T for 15sec/each 
and blocked with 200μL commercial blocking buffer (Thermo Fisher Inc.) for 1h at RT. After a 
course of washing with 1xPBS-T for three times, the plate was incubated with the investigated 
sera [(100μL), diluted 1:500 in PBS to blocking buffer (1:1), 1% normal goat serum (v/v) and 1% 
normal rabbit serum (v/v)] overnight at 4°C. After a another course of washing, the plate was 
loaded with 100μL of horseradish peroxidase-conjugated, affinity purified isotype-specific rabbit 
anti-chicken IgY antibody (Thermo Fisher Scientific Inc., Rochester, NY).  
The dilution of the secondary antibody was 1:30,000 in bovine serum albumin (BSA) in blocking 
buffer and 1% normal goat serum (v/v). The plate was set for 1h at RT and a course of 5x washing 
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followed. For developing the color reaction, we used OptEIATM TMB substrate (BD, Lakes, NJ). 
The color developing process was following the manufacturer instructions and the reaction 
terminated by adding 1N sulfuric acid (50μL/well) after 5min for all the trials.  
Absorbance was measured by using BioTeK microplate reader (BioTek Instruments, Inc., 
Winooski, VT, USA) at 450nm using Gen5 version data analysis software (BioTek Inc) (Layton 
et al., 2009; Kuttappan et al., 2015).  
3.2.6. Statistical analyses 
The relative average levels of the anti-peptide antibody in the sera was normalized by calculating 
the value of each sample (n=20) to the mean value of the non-immunized group as the negative 
control (S-N). The average mean of the readings of the non-immunized birds was the baseline to 
calculate the S-N values of all groups. Results were analyzed using one-way analysis of variance 
(ANOVA) with least significant differences (L.S.D.) of the means of the S-N values and Student’s 
t-test were used to determine the significant differences between the treatments. All data were 
analyzed using JMP software (SAS institute Inc., Cary, NC, software by the University of 
Arkansas). Statistical differences of the RCA-peptide immunized group were at level p<0.0001 
(Chou et al., 2016). 
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3.3.RESULTS AND DISCUSSION 
3.3.1. Evaluation of the anti-Me2 antibody titers 
The pioneer work of activating the CD40 receptor by artificial agonists had encourage many 
laboratories to further investigating the outcome of this activation (Li and Ravetch, 2011; Richman 
and Vonderheide, 2014b). In essence, natural or artificial activation of this receptor could lead to 
many desirable effects over the course of the acquired immune response. When B cell involved in 
CD40-CD40L crosslinking, high antibody titer, antibody isotype-switching and affinity 
maturation are obvious (Amitage and Alderson, 1995; Merluzzi et al., 2004). In this experimental 
design, we tested the ability of DNA aptamers-based RCA products to act as an adjuvant directed 
toward the CD40 receptor and indirectly conjugated with influenza M2e peptide. The same RCA 
products has previously shown the ability to agonist the CD40 receptor in chicken macrophage 
HD11 cell line (data unpublished). We compared our immune complex [(2)RCA products-SA-
(2)peptide] (Figure 3.1) in two different doses with several negative control groups [SA-(2)RCA 
products alone, SA-(2)peptide alone, or non-immunized group) and with our previous immune 
complex design [(2)MAb-SA-peptide(2)] (Table 3.1). As stated by our group previously, chicken 
immunized with agonistic anti-CD40 MAb conjugated with low immunogenic peptide could 
induce high antibody titer directed against this particular peptide (Chen et al., 2012). Currently, 
our results showed that the administration of 50μg/bird of RCA products-peptide immune complex 
could induce significant level of anti-peptide IgG titer for long term at level p=0.0001 (Figure 
3.2B). The high antibody titer was detected as early as 7 days post immunization and remained 
high till the end of the experiment especially for birds with the high dose. These results are ideally 
match with our group novel work when the MAb was used as the adjuvant with the same dose and 
route (Figures 3.2A and 3.2B).  
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The same immune complex at lower dose (25μg/bird) failed to induct significant level of anti-
peptide IgG in the sera at 7 or 14 days post first immunization. However, this particular 
immunization needed boosting at day 21 to induct significant level of the antibody titer at 28 days 
post immunization (Figures 3.2A and 3.2B, Figure 3.3). Our results showed no need to use booster 
dose to gain satisfactory level of anti-peptide IgG titer at dose 50μg/bird (Table 3.2). Boosting 
could apply additional undesired effects especially in broiler chickens such as immune stress and 
cost. All birds showed retarded immune response at day 14 post immunization (boost timing) 
(Figure 3.3A). We recorded some management issues during the day before the onset of blood 
sampling. This might stressed out the birds at that particular time. However, it seems that the birds 
have compensated the immune response against the immunogen in later weeks. 
 
3.4.CONCLUSIONS AND SIGNIFICANCE 
The M2e protein is highly expressed on the surface of the naturally infected cells with influenza 
virus. However, the M2e is poorly immunogenic by its own (Black et al., 1993; Feng et al., 2006). 
It is obvious that MAb adjuvants attached to soluble peptide hapten targeting the CD40 receptor 
yields better-enhanced long lasting immune response than traditional adjuvants (Barr et al., 2003; 
Martin et al., 2017; Vuong et al., 2018). Despite the use of relatively low concentration of the 
hapten (M2e peptide), our RCA products-peptide immune complex succeeded to induct high level 
of anti-M2e IgG antibody titer in the chicken sera at dose (50μg/bird). With this dose, the elevation 
of the antibody titer started as early as seven days post-immunization and remained high to the end 
of the experiment. The action of this immune complex proves that this complex is with high 
potency and efficacy (Deng et al., 2015). These results are comparable to our lab group previous 
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work with MAb as the adjuvant with the same peptide (Chou et al., 2016; Vuong et al., 2018). 
However, lower dose of the same complex (25μg/bird) yielded only minor level of the antibody 
titer and needed a booster dose to sustain relatively acceptable level of the same antibody titer at 
the end of the experiment. 
Our immune adjuvant could guarantee the work as a universal adjuvant with any short soluble 
antigenic peptide. The immune response course with this DNA aptamers-based RCA products 
immunogenic adjuvant would pass through APCs-TH cells interaction pathway.   
Finally, aptamers are replacing the MAbs in many in vitro assays such as ELISA especially in 
vaccines assessment (Yoon et al., 2017; Trausch et al., 2017). We are first reporting targeting the 
CD40 receptor with DNA aptamers as a vaccine adjuvant. This would offer a cheaper molecule 
and easier to prepare molecule with high stability. This would improve the effectiveness of many 
vaccines not in the husbandry field but also in vaccinology in general.  
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3.5.TABLES 
Table 3.1. RCA Template, primer and spacer complementary sequence designs. The RCA 
template composed of partial primer-binding sequences at the upstream and the downstream. The 
primer utilized to circularize the template with the aid of T4 DNA ligase enzyme. The template 
composed of the complementary sequences of two aptamers separated by spacer to ensure 
individual effect of each aptamer and to avoid dimerization.  
Description Sequence (5’ 3’) 
RCA products 
template 
GCA TCT GAA C GCG GGA CGT AGC ATA AAA GAC GAA TTC ACT 
GCT CCA TTT ACA CCC CAT TAC CAA TTC CAC CTC TTG TCC TTC 
GAA TTC GG GAT CCA CCG GTA GCA GCG GGA CGT AGC ATA AAA 
GAC CTA GCC CTG CTC TTC TGA TCC CTA TTC CAT GTA GCC CTA 
CTC TTG TCC TTC GAA TTC GG GGA ACG TCT T 
RCA primer GTT CAG ATG CAA GAC GTT CC 
Spacer GAT CCA CCG GTA GCA 
Single underline represents the primer-binding site and the double underline represents the 
spacer complementary sequence 
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Table 3.2. Description of the experimental design. Six groups (n=20) were raised in a comingle 
pen and immunized with two different doses of RCA-SA-peptide immune complex (i.e. low: 
25μg/bird and high: 50μg/bird) for two times. This immune complex composition was compared 
with anti-chicken CD40 monoclonal antibody-based immune complex that has been given at 
(50μg/bird) for two times as well, and with three negative control groups. 
 
Group Description Dose/bird Prime/route Boost/route 
Non-immunized NA NA NA NA 
NC SA-peptide(2) 0.2μg D7/SC D21/SC 
NC SA-RCA(2) 50μg D7/SC D21/SC 
MAb-based adjuvant (2)MAb-SA-peptide(2) 50μg-0.2μg D7/SC D21/SC 
RCA-based adjuvant (2)RCA-SA-peptide(2) 25μg-0.2μg D7/SC D21/SC 
RCA-based adjuvant (2)RCA-SA-peptide(2) 50μg-0.2μg D7/SC D21/SC 
⸸Immune complexes was prepared in a volume of 0.4mL/dose/bird emulsified PBS (containing 
5% [v/v] squalene and 0.4% [v/v] Tween 80, pH=7.4) 
*Doses of SA-(2)peptide and (2)MAb 2C5-SA-(2)peptide were calculated according to Chen et 
al., 2012. Values represent RCA and M2e concentrations, respectively. 
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Table 3.3. Normalized S-N values of the ELISA results of the anti-M2e IgG antibody in 
chicken sera. The (S) is the average sample reading and (N) is the average mean of the readings 
of the non-immunized group. Chickens were divided randomly into 6 groups in a comingle pen 
(n=20) and immunized at two timing (days 7 and 21). Investigated immune complex (RCA-M2e) 
was with two different doses (i.e. low: 25μg/bird and high: 50μg/bird). Blood collected at weekly 
intervals to apply ELISA assay. The sera diluted at 1:500 and the assay run in duplicates. 
Significant differences between groups were calculated by comparing means ± SE of the S/N 
values by ANOVA and student t-test (JMP software, SAS institute Inc., Cary, NC, software by the 
University of Arkansas). Different letters represent significant differences at level p=0.0001 
Group D7PI  
(Mean±SE) 
D14PI  
(Mean±SE)(Boost) 
D21PI  
(Mean±SE) 
D28PI  
(Mean±SE) 
Non-immunized 1 ± 0.0341
d
 1 ± 0.0155
d
 1 ± 0.0178
d
 1 ± 0.0176
d
 
M2e only 1.1368 ± 0.0315
bc
 1.0935± 0.0128
bc
 1.0281 ± 0.0122
d
 1.0724 ± 0.022
cd
 
RCA only 1.0901 ± 0.0326
cd
 1.0597 ± 0.0301
cd
 1.0956 ± 0.0167
c
 1.1131 ± 0.0141
c
 
MAb-peptide (50μg/bird) 1.2190 ± 0.0693
a
 1.557 ± 0.0267
ab
 1.2206 ± 0.0280
b
 1.4735 ± 0.0269
a
 
RCA-peptide (25μg/bird) 1.0487 ± 0.0573
cd
 1.0561 ± 0.0159
cd
 1.2170 ± 0.0223
b
 1.2220 ± 0.0215
b
 
RCA-peptide (50μg/bird) 1.2990 ± 0.0347
a
 1.1742 ± 0.0271
a
 1.3017 ± 0.0257
a
 1.4343 ± 0.0462
a
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3.6.FIGURES  
 
Figure 3.1: schematic figure represents the design of the immune complex. Streptavidin (SA) 
is the central molecule that holds the biotinylated components of the immune complex tightly. 
RCA molecule was biotinylated to conjugate with the SA. Similarly, the biotinylated M2e peptide 
was mixed with the RCA in 1 to 1 ratio on the molecular basis. RCA-M2e mix then added to SA 
in 2 to 1 ratio on molecular basis as well. The design followed what described by Chen et al. 2010. 
Streptavidin-biotin model: Trong et al., 2011, M2e model: Cho et al., 2015.  
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Figure 3.2. Normalized ELISA results representing S-N values of the anti-M2e IgG in 
chicken sera at weekly intervals after immunization. Birds were immunized at day 7 and day 
21 via s/c route with RCA-peptide complex in two different doses (50μg/bird) or (25μg/bird) 
(n=20). The normalization calculations S-N = the average of (sample read – mean reads of the 
non-immunized group). The mean of each group calculated accordingly. The significant 
differences of the antibody titers between the group that received 50ug/bird of the RCA-peptide 
immune complex and the non-immunized group are according to ANOVA and student t-test. 
Asterisks represent statistical differences (p=0.0001) from the non-immunized control group. A) 
Results according to the timing after immunization; B) Results according to groups. 
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Figure 3.3. Normalized ELISA results representing S-N values of anti-peptide IgG in chicken 
sera at weekly intervals.  Results shown at D0-D28 post-immunization with RCA-peptide 
(50μg/bird) or RCA-peptide (25μg/bird). Birds were immunized at day 7 and day 21 
subcutaneously (n=20/group) and blood sampling performed at weekly intervals.  Birds 
immunized with the higher dose showed significant differences to the non-immunized group as 
early as D7PI, whereas, birds immunized with the lower dose showed significant differences only 
at D21PI. Results show mean ± SE and the differences are according to ANOVA and student t-
test. Asterisks represent statistical differences (*p=0.0001) from the non-immunized group. 
  
113 
3.7.REFERENCES 
Abbas, A. K., A. H. Lichtman and S. Pillai. 2012. Innate immunity. In: Cellular and Molecular 
Immunology, 7th ed. Eds. Abbas, A. K., A. H. Lichtman and S. Pillai. Elsevier Saunders, USA. 
55-88. 
Abbas, A. K., A. H. Lichtman and S. Pillai. 2015. Differentiation and function of CD40+ effector 
T cells. In: Cellular and Molecular Immunology, 8th ed. Eds. Abbas, A. K., A. H. Lichtman 
and S. Pillai. Elsevier Saunders, USA. 213-230. 
Ali, M. M, F. Li, Z. Zhang, K. Zhang, D. Kang, J. A. Ankrum, X. C. Le, and W. Zhao. 2014. 
Rolling circle amplification: a versatile tool for chemical biology, materials science and 
medicine. Chem. Soc. Rev. 43: 3324-3341. 
Amitage, R. J., and M. R. Alderson. 1995. B-cell stimulation. Curr. Opin. Immunol. 7: 243-247. 
Barr, T. A., A. L. McCormick, J. Carlring, and A. W. Heath. 2003. A potent adjuvant effect of 
CD40 antibody attached to antigen. Immunology. 109: 87-92. 
Beatty, G. L., Y. Li, and K. B. Long. 2017. Cancer immunotherapy: activating innate and adaptive 
immunity through CD40 agonists. Expert Rev. Anticanc. Ther. 17(2): 175-186. 
Black, R. A., P. A. Rota, N. Gorodkova, H. Klenk, and A. P. Kenda. 1993. Antibody response to 
the M2 protein of influenza A virus expressed in insect cells. J. Gen. Virol. 74: 143-146.  
Blanco, L., A. Bernad, J. M. Luzaro, G. Martin, C. Garmendia, and M. Salas. 1989. Highly 
efficient DNA synthesis by the phage ɸ29 DNA polymerase. J. Biol. Chem. 264(15): 8935-
8940. 
Bosson, C., K. Ingold, A. Tardivel, J. Bodmer, O. Gaide, S. Hertig, C. Ambrose, J. Tschopp, and 
P. Schneider. 2006. Interactions of tumor necrosis factor (TNF) and TNF receptor family 
members in the mouse and human. J. Biol. Chem. 281(20): 13964-13971. 
Caux, B., C. Massacrier, B. Vanbervliet, B. Dubois, C. Van Kooten, I. Durand, and J. Banchereau. 
1994. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180: 1263-
1272. 
Chen, C.; Abi-Ghanem, D.; Njongmeta, L.; Bray, J.; Mwangi, W.; Waghela, S. D.; McReynolds, 
J. L.; Ing, N. H. and Berghman, L. R. 2010. Production and characterization of agonist 
monoclonal antibodies against chicken CD40. Develop. Comp. Immunol. 34: 1139-1143.  
Chen, C.; Abi-Ghanem, D.; Waghela, S. D.; Chou, W.; Farnell, M. B.; Mwangi, W., and 
Berghman, L. R. 2012. Immunization of chicken with an agonistic monoclonal anti-chicken 
CD40 antibody-hapten cpmlex: Rapid and Robust IgG response induced by a single 
subcutaneous injection. J. Immunol Methods. 378: 116-120. 
Cho, K. J., B. Schepens, J. H. Seok, S. Kim, K. Roose, J. Lee, R. Gallardo, E. Van Hamme, J. 
Schymkowitz, F. Rousseau, W. Fiers, X. Saelens, and K. H. Kim. 2015. Structure of the 
114 
extracellular domain of the matrix protein 2 of influenza A virus in complex with a protective 
monoclonal antibody. J. Virol. 89(7): 3700-3711. 
Deng, L., K. J. Cho, W. Fiers, and X. Salens. 2015. M2e-based universal influenza A vaccines. 
Vaccines. 3, 105-136; DOI: 10.3390/vaccines 3010105  
Eliopoulos, A. G., C. Davies, P. G. Knox, N. J. Gallagher, S. C. Afford, D. H. Adams, and L. S. 
Young. 2000. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic 
ligands of the tumor necrosis factor superfamily. Mol. Cell. Biol. 20(15): 5503-5515. 
Ellington, A. D., and J. W. Szostak. 1990. In vitro selection of RNA molecules that bind specific 
ligands. Nature. 346: 818-822 
Feng, J., M. Zhang, K. Mozdzanowska, D. Zharikova, H. Hoff, W. Wunner. R. B. Couch, and W. 
Gerhard. 2006. Influenza A virus infection engenders a poor antibody response against the 
ectodomain of matrix protein 2. Virol. J. 3(102): 1-13. 
Gardell, J. F., and D. C. Parker. 2017. CD40L is transferred to antigen-presenting B cells during 
delivery of T-cell help. Eur. J. Immunol. 47: 41-50. 
Gerlach, A., A. Steimle, L. Krampen, A. Wittmann, K. Gronbach, J. Geisel, I. B. Autenrieth, and 
J. Frick. 2012. Role of CD40 ligation in dendritic cell semi maturation. BMC Immunol. 13(22): 
1-11. 
Graf, D., S. Müller, U. Korthäuer, C. van Kooten, C. Weise and R. A. Kroczek, R. A. 1995. A 
soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur. J. Immunol. 
25: 1749-1754. 
Han, S., K. Hathcock, B. Zhang, T. B. Kepler, R. Hodes, and G. Kelsoe. 1995. Cellular interaction 
in germinal centers. Roles of CD40 ligand and B7-2 in established germinal center. J. Immunol. 
155: 556-567.  
Hollenbaugh, D., L. S. Grosmaire, C. D. Kullas, N. J. Chalupny, S. Braesch-Andersen, R. J. 
NoelIe, I. Stamenkovic, J. A. Ledbetter and A. Aruffo. 1992. The human T cell antigen gp39, 
a member of the TNF gene family, is a ligand for the CD4O receptor: expression of a soluble 
form of gp39 with B cell co-stimulatory activity. EMBO J. 11(12): 4313-4321 
Jayasena, S. D. 1999. Aptamers: an emerging class of molecules that rival antibodies in 
diagnostics. 45(9): 1628-1650. 
Johne, R., H. Muller, A. Rector, M. van Ranst, and H. Stevens. 2009. Rolling-circle amplification 
of viral DNA genomes using phi29 polymerase. Tren. Microbiol. 17(5): 205-211. 
Kawabe, T., M. Matsushima, N. Hashimoto, K. Imaizumi, and Y. Hasegawa. 2011. CD40/CD40 
ligand interactions in immune responses and pulmonary immunity. Nagoya J. Med. Sci. 73: 69-
78.  
115 
Kawabe, T., T. Naka, K. Yoshida, T. Tanaka, H. Fujiwara, S. Suematsu, N. Yoshida, T. Kishimoto, 
and H. Kikutani. 1994. The immune response in CD40-deficient mice: impaired 
immunoglobulin and germinal center formation. Immunity. 1(3): 167-178. 
Kelly, L. M., B. S. Rlat, and L. C. Alworth. 2013. Techniques for collecting blood from the 
domestic chicken. Clinic. Tech. 42(10): 359-361. 
Kuttappan, V. A., L. R. Bielke, A. D. Wolfenden, L. R. Berghman, G. Tellez, B. M. Hargis, and 
O. B. Faulkner. 2015. Comparison of different ELISA protocols for the detection of IgA against 
influenza nucleoproteins in trachea of vaccinated chickens. Poult. Sci. 94:181–184. 
Layton, S. L., D. R. Kapczynski, S. Higgins, J. Higgins, A. D. Wolfenden, K. A. Liljebjelke, W. 
G. Bottje, D. Swayne, L. R. Berghman, Y. M. Kwon, B. M. Hargis, and K. Cole. 2009. 
Vaccination of chickens with recombinant Salmonella expressing M2e and CD154 epitopes 
increases protection and decreases viral shedding after low pathogenic avian influenza 
challenge. Poult. Sci. 88 :2244–2252 
Li, F. and J. V. Ravetch. 2011. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor 
activities of agonistic CD40 antibodies. Science. 333(6045): 1030-1034. 
Lumeij, J. T. 1987. Avian clinical pathology. General considerations. Vet. Quart. 9(3): 249 – 254. 
DOI. org/10.1080/01652176. 1987.9694109 
Ma, D. Y. & E. A. Clark. 2009. The role of CD40 and CD40L in dendritic cells. Semin. Immunol. 
21(5), 265-272. 
Ma, J., T. Chen, J. Mandelin, A. Ceponis, N. E. Miller, M. Hukkanen, G. F. Ma, and Y. T. 
Konttinen. 2003. Regulation of macrophage activation. CMLS, Cell. Mol. Life. Sci. 60: 2334-
2346. 
Martin, C., S. D. Waghelal, S. Lokhandwala1, A. Ambrus, J. Bray, C. Vuong, V. Vinodkumar, P. 
J. Dominowski, S. Rai, D. Mwangi, D. L. Foss, and W. Mwangi. 2017. Characterization of a 
broadly reactive anti-CD40 agonistic monoclonal antibody for potential use as an adjuvant. 
PLoS ONE. 12(1): e0170504.  
Merluzzi, S., M. Moretti, S. Altamura, P. Zwollo, M. Sigvardsson, G. Vitale, and C. Pucillo. 2004. 
CD40 stimulation induces Pax5/BSAP and EBF activation through a APE/Ref-1-dependent 
Redox mechanism. J. Biol. Chem. 279(3): 1777-1786. 
Noy, R., and J. W. Pollard. 2014. Tumor-associated macrophages: from mechanism to therapy. 
Immunity. 41(10): 49-61. 
Okoye, I. S., and M. S. Wilson. 2011. CD4+ T helper 2 cells – microbial triggers, differentiation 
requirements and effector functions. Immunol. 134: 2368-377.  
Pinchuk, M., P. S. Polacino, M. B. Agy, S. J. Klaus, and E. A. Clark. 1994. The role of CD40 and 
CD80 accessory cell molecules in dendritic cell-dependent HIV-1 infection. Immunity. 1(4): 
317-325.  
116 
Rakhmilevich, A. L., K. L. Alderson, and P. M. Sondel. 2012. T-cell-independent antitumor effects 
of CD40 ligation. Int. Rev. Immunol. 31(4): 267-278. 
Richman, L. P., and R. H. Vonderheide. 2014a. Anti-human CD40 monoclonal antibody therapy 
is potent without FcR crosslinking. OncoImmunology 3:e28610. DOI: org/10. 4161/onci. 
28610 
Richman, L. P., and R. H. Vonderheide. 2014b. Role of crosslinking for agonistic CD40 
monoclonal antibodies as immune therapy of cancer. Cancer Immunol. Res. 2(1): 19-26. 
Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured 
human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus 
interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179: 1109-1118. 
Schoenberger, S. P., R. E. M. Toes, E. I. H. van der Voort, R. Offringa and C. J. M. Melief. 1998. 
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interaction. Nature. 393: 
480-483.  
Scott, M. J., M. J., J. J. Hoth, M. K. Stagner, S. A. Gardner, J. C. Peyton, and W. G. Cheadle. 2004. 
CD40–CD154 interactions between macrophages and natural killer cells during sepsis are 
critical for macrophage activation and are not interferon gamma dependent. Clin. Exp. 
Immunol. 137: 469-477. 
Song, K., S. Lee, and C. Ban. 2012. Aptamers and their biological applications. Sensors. 12: 612-
631. 
Stout, R. D. & J. Suttles. 1996. The many roles of CD40 in cell-mediated inflammatory responses. 
Immunol. Today. 17(10), 487-492. 
Suttles, J. & R. D. Stout. 2009. Macrophage CD40 signaling: a pivotal regulator of disease 
protection and pathogenesis. Semin. Immunol. 21(5), 257-264. 
Thaiss, C. A., V. Semmling, L. Franken, H. Wagner, and C. Kurts. 2011. Chemokines: a new 
dendritic cell signal for T cell activation. Front. Immunol. 2: 31. DOI: 
10.3389/fimmu.2011.00031 
Trausch, J. J., M. Shank-Retzlaff, and T. Verch. 2017. Replacing antibodies with modified DNA 
aptamers in vaccine potency assays. Vaccine. 35: 5495-5502. 
Trong, I. L., Z. Wang, D. E. Hyre, T. P. Lybrand, P. S. Stayton, and R. E. Stenkamp. 2011. 
Streptavidin and its biotin complex at atomic resolution. Acta. Cryst. D67: 813-821. 
Tubo, N. J., and M. K. Jenkins. 2014. TCR signal quantity and quality in CD4+ T cell 
differentiation. Trends in Immunol. 35(12): 591-596.  
Tuerk, C., and L. Gold. 1990. Systemic evolution of ligand by exponential enrichment: RNA 
ligands to bacteriophage T4 DNA polymerase. Science. 249, 505-510. 
117 
Van Kooten, C. and J. Banchereau. 1997. Functions of CD40 on B cells, dendritic cells and other 
cells. Current Opinion in Immunol. 9: 330-337. 
Vonderheide, R. H., and M. J. Glennie. 2013. Agonistic CD40 antibodies and cancer therapy. Clin. 
Cancer Res. 19(5): 1035-1043. 
Vuong, C. N., W. Chou, W. Briggs, O. Faulkner, A. Wolfenden, M. Jonas, D. R. Kapczynski, B. 
M. Hargis, L. R. Bielke, and L. R. Berghman. 2018. Crude inactivated influenza A virus 
adjuvanted with a bispecific antibody complex targeting chicken CD40 and AIV M2e confers 
protection against lethal HPAI challenge in chickens. Monoclon. Anti. Immunol. Immunothe. 
37(6):245-251. 
Yellin, M. J., K. Sippel, G. Inghirami, L. R. Covey, J. J. Lee, J. Sinning, E. A. Clark, L. Chess and 
S. Lederman. CD40 molecules induce down-modulation and endocytosis of T cell surface T 
cell-B cell activating molecule/CD40-L. Potential role in regulation helper effector function. J. 
Immunol. 152: 598-608. 
Yoon, S. Y., G. Gee, K. Hong, and S. Seo. 2017. Application of aptamers for assessment of vaccine 
efficacy. Clinic. Exp. Vaccine. 7(6): 160-163. 
  
118 
CHAPTER IV 
Efficient Correction of Heteroduplex DNA Formed during PCR Amplification of DNA 
Aptamer Libraries 
 
Adil Sabr Al-Ogaili1,2, Billy M. Hargis1,3 and Young Min Kwon1,3,* 
 
 
1Department of Cell and Molecular Biology, University of Arkansas, Fayetteville, AR 72701.  
2Kut Technical Institute, Middle Technical University, Baghdad, Iraq, 00964.  
3Center of Excellence for Poultry Science, University of Arkansas, Fayetteville, AR 72701. 
 
 
 
 
 
 
 
*Corresponding author: 
Young Min Kwon 
Department of Poultry Science 
University of Arkansas 
1260 W. Maple St. 
Fayetteville AR, 72701 
Phone: (479) 575-4935 
Email: ykwon@uark.edu 
 
119 
ABSTARCT 
DNA aptamers are now emerging as a promising target-recognizing biomolecule of choice in 
various biomedical and biotechnological applications with multiple advantages. Traditional 
aptamer selection process is through systemic evolution of ligands by exponential enrichment 
(SELEX) procedure, which includes multiple PCR steps to amplify the enriched aptamers. During 
amplification, unwanted DNA byproducts of considerable amount are often formed. These 
spurious byproducts as characterized by DNA fragments, which appear in variable lengths on gel 
electrophoresis, are considered as the result of formation of heteroduplexes within the randomized 
region of the DNA aptamer library. These PCR byproducts negatively alter the diversity and 
composition of the DNA library. Here we describe a simple method that corrects these PCR 
byproducts efficiently. When repetitive cycles of heating-cooling (60ºC20ºC) were applied to 
the enriched aptamers, our results showed that this procedure has efficiently removed the 
formation of the byproducts, suggesting that this method can be used widely in removing 
heteroduplexes or other type of spurious byproducts formed during amplification of DNA aptamer 
library. 
Keywords: DNA aptamer, PCR byproducts, DNA heteroduplexes, SELEX. 
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4.1.INTRODUCTION 
The technique of systemic evolution of ligands by exponential enrichment (SELEX) was initially 
developed independently and simultaneously by two laboratories in 1990 (Tuerk and Gold, 1990; 
Ellington and Szostak, 1990). This technique has been used extensively to develop nucleic acid 
aptamers with high specificity and affinity to various targets for variable applications. In fact, 
aptamers have been replacing monoclonal antibodies in many biological and biochemical 
applications (Jayasena, 1999; Dollins et al., 2008; Scoville et al., 2017).  
The procedure of SELEX requires randomized oligonucleotide library that is flanked by two 
constant regions at the upstream and the downstream, which serve as primer binding sites for 
subsequent PCR amplification. Oligonucleotide library generation depends on equal opportunity 
of the four-nucleotide bases incorporated at any position within the variable region. Depending on 
the length of the random region, the predicted diversity of the oligonucleotide library is 4n where 
(4) represents the four nucleotides, i.e., A, C, G and T and n is the length of the random variable 
region. For example, a library with 40n at the random region form 1024 different sequence 
hypothetically (Vorobyeva et al., 2018). At the ends of each SELEX enrichment cycle, the PCR is 
used to amplify the enriched aptamers exponentially. In the later step, the double-stranded DNA 
products of the PCR are typically converted into single stranded DNA (ssDNA) by the digestion 
with an exonuclease enzyme (e.g. lambda exonuclease – λ- exonuclease) to resume the original 
library format for the new enrichment cycle (Avci-Adali et al., 2010). However, due to highly 
diverse sequence of the library, there is always a possibility to develop amplify spurious 
byproducts during the PCR steps. Many sequences in the random library might undergo partial 
hybridization between different sequences to form PCR byproducts with variable lengths (Smyth 
et al., 2010; Tolle et al., 2014; Thompson et al., 2002). Another source of the PCR byproducts can 
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arise when one or both primers fully or partially hybridize to other regions than the constant 
primer-annealing sites. In essence, the correct PCR products are usually mixed with one or two 
types of byproducts; i.e. smearing bands and/or ladder-like byproducts when analyzed by agarose 
gel electrophoresis. In either way, the PCR byproducts might affect negatively the diversity of the 
enriched aptamers. There are studies suggesting practical methods to resolve this issue through 
PCR re-conditioning (Smyth et al., 2010; Tolle et al., 2014; Thompson et al., 2002; Qiu et al., 
2001).  
Here, we describe a method that could efficiently correct the size and the shape of the PCR 
byproducts that occur during SELEX DNA aptamer selection. We hypothesized that the 
application of appropriate thermal cycles might partially denature these heteroduplexes, 
facilitating homoduplexes formation. PCR byproducts are considered to be formed due to the 
formation of DNA heteroduplexes when mixing more than one template sequence en masse 
(Ruano and Kidd, 1998; Kalle et al., 2014). Our thermal cycle involves raising the temperature of 
the DNA byproducts to 65°C for 10 min and cool them down to 20°C for 1 min, which was 
repeated for six times. 
With our method, however, the fully hybridized homoduplexes would not be affected due to their 
very low free energy change (ΔG) value (Petruska and Goodman, 1995). Our results showed 
marked reduction in the ladder-like and/or smearing band PCR byproducts. Analysis of the 
resulting library by Illumina sequencing demonstrated that there was a marked reduction in the 
proportion of the shorter and longer reads in the enriched library by these corrective cycles in 
comparison to the negative control library. Here, we describe a simple and an effective method 
that corrects the undesirable PCR byproducts to improve overall quality of the aptamers library. 
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4.2.MATERIALS AND METHODS 
4.2.1. DNA library and primers.  
A randomized single-stranded DNA (ssDNA) library, forward and reverse primers were purchased 
from Integrated DNA Technologies (IDT, Coralville, Iowa, USA). The library was composed of 
two parts; a variable region of 40 nucleotides, which was flanked by two constant regions that 
consisted of 20 nucleotides each at the upstream and the downstream. The fixed regions consisted 
of the sequence for annealing of the forward primer at the upstream and reverse primer binding 
site sequence at the downstream. The library sequence was 5’-CCG AAT TCG AAG GAC AAG 
AG (N)
40
 TCT TT TAT GCT ACG TCC CGC-3’, whereas the forward and the reverse primers 
sequences were: 5’-CCG AAT TCG AAG GAC AAG AG-3’ and 5’-GCG GGA CGT AGC ATA 
AAA GA-3, respectively. Our library was with 1024 sequence hypothetically. The reverse primer 
was phosphorylated at the upstream for digestion with λ-exonuclease enzyme in the later step 
during the enrichment cycles. The library and the primers were diluted in 1X Tris-EDTA buffer 
(TE buffer, ThermoFisher Scientific, USA) to sustain 100μM concentration as recommended by 
the manufacturer and were stored in -20°C. 
4.2.2. Target protein  
The target protein used for the aptamers selection was a recombinant protein of chicken CD40 
extracellular domain protein (chCD40ED). The protein was a kind gift from Dr. Berghman at the 
University of Texas A&M. Briefly according to Chen and co-workers (2010), total RNA was 
isolated from chicken spleen and cDNA was synthesized accordingly. The sequence encoding the 
chCD40ED, which was already determined, was amplified with nested PCR and the gene encoding 
the protein was cloned into expression vector pcDNA5 (Invitrogen). The chCD40ED recombinant 
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protein was expressed in hybridomas, human embryonic kidney (HEK)-293 Freestyle cells in 
protein-free medium (Antagene Inc., Santa Clara, CA, USA) with concentration of 1mg/mL. The 
protein’s stock was diluted with sterile 1X phosphate buffer saline (1XPBS, w/v) to concentration 
of 15μg/L and aliquoted into 1ml in sterile tubes and stored at –80°C. 
4.2.3. In vitro SELEX procedure  
Ten enrichment cycles were applied to develop the specific aptamers to the target protein. The 
procedure for aptamer selection was performed as described elsewhere (Tuerk and Gold, 1990; 
Ellington and Szostak, 1990). Briefly, a 35μL from the ssDNA library (1μg/μl) was mixed with 
115μL binding buffer (50mM Tris HCl, 25mM NaCl, 5mM MgCl2, 10mM DTT (dithiothreitol), 
pH 7.5) and was denatured by heating at 95°C for 10min, cooled to 4°C for 5 min and incubated 
at room temperature (RT) for 10min. The mixture filtered three times through nitrocellulose filter 
membrane (0.45um) (Ref# HAWP01300, Merck Millipore Ltd, Ireland) hold by filter holder 
(“pop-top”, Millipore, MA, USA) to get rid of non-specific bounders. 50μL (15μg/L) of the target 
protein was incubated with library-in-binding buffer with rotation for 1hr at RT. The library-
protein mixture passed through another nitrocellulose filter membrane to trap the enriched 
aptamers. The filter then immersed in 200μl of pre-heated (60ºC) elution buffer (0.4 M sodium 
acetate, 5mM EDTA, 7M urea; pH 5.5) for 5min. The eluted material was diluted with 200μl 
ddH2O and the DNA was precipitated with ethanol precipitation method (Wang and Li, 2013).  
4.2.4. Amplification and digestion of the DNA  
After each enrichment cycle, the enriched ssDNA aptamers were amplified with 25 cycles of PCR 
amplification. The PCR was conducted using G2 Hot Start Green Master Mix (Cat# M7422, 
Promega). The reaction mix was 1μl (10μM) from the of the DNA library (enriched aptamers in 
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the later cycles) as the template, 1μl of each forward and phosphorylated reverse primers (4μM), 
12.5μl of 2X reaction buffer (pH 8.5). The reaction buffer composed of 2.5U of the polymerase 
enzyme, 400μM of each dNTPs and 4mM MgCl2. Nuclease-free water was added to adjust the 
final reaction volume to 25μl. The thermal cycles composed of 95°C for 5min as the denaturing 
step, followed by 25 thermal cycles composed of 95°C for 30sec, 56°C for 15sec and 72°C for 
15sec. The final extension was at 72°C for 5min. The PCR products were monitored on 1% agarose 
gel stained with SYBR Safe dye (ThermoFisher Scientific, USA). The PCR-resulted double-
stranded DNA (dsDNA) was subjected to the action of λ exonuclease enzyme (Cat# M0262S, 
NEB, USA) to retain the ssDNA for the next round. The reverse primer was order as 
phosphorylated to facilitate this task (Table 4.1). The digestion reaction conditions were as 
described by the manufacturer. 
4.2.5. Correcting thermal cycles  
After each amplification of the enriched aptamers, the PCR products were ethanol precipitated, 
purified and re-suspended initially in 100μL 1X TE buffer (v/v). In general, the final concentration 
of the DNA in the 1X TE buffer (w/v) was ~150 ng/μl. We aliquoted the diluted DNA into 50μl 
in PCR tubes (Cat# N80105580, ThermoFisher).  Then, the purified DNA were subjected to six 
correcting thermal cycles using thermocycler (PTC-200, Peltier Thermal Cycler). The protocol 
involved raising the temperature to 65°C for 10 min, cool down to 20°C for 1min and this cycle 
was repeated for six times. After the sixth cycle, the DNA was monitored on 1% agarose gel (see 
Amplification and digestion of the double-stranded DNA). 
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 4.2.6. Illumina sequencing 
The procedure for Illumina sequencing was as previously described (Scoville et al., 2017). The 
bioinformatics analysis was performed using the free online software “Galaxy Bioinformatics” 
(open access software) (Thiel and Giangrande, 2016; Kinghorn et al., 2018).  Briefly, samples 
from rounds 1, 6, 8 and 10 were prepared for Illumina sequencing platforms. The enriched DNA 
aptamers from each selected rounds were barcode-tagged and were used as a template for PCR 
amplification using primers with Illumina adapter sequences. The DNA aptamers were diluted in 
nuclease-free water to the concentration of 10μM. The Illumina adapter primers, which also 
include unique index sequences for different samples, were utilized to amplify the templates. 
Twenty-five PCR cycles were applied using Q5 hot start high-fidelity DNA polymerase and buffer 
(Cat # M0493S, NEB). The resulting PCR products were combined at ultimately the same amount 
and concentration (50.4 ng/μl). The mixed DNA samples were PAGE-purified using 4-20 % 
polyacrylamide gel (Life Technologies, NY, USA), and was sent for Genomics Core Facility at 
the University of California at Riverside, USA for Illumina sequencing using MiSeq with 151 
cycles in single-end mode. 
The results from the Illumina sequencing were analyzed using multiple commands in the Galaxy 
tool. The total number of the reads by the Illumina sequencing were about 16 millions. These reads 
were tracked according to their index sequences. The quality of the reads, the lengths of the reads 
and the conserved sequences were investigated as described previously (Thiel and Giangrande, 
2016; Thiel, 2016). The total number of the reads by the Illumina sequencing were about ~16 
million reads, however, about 5% of the total reads was neglected due to their improper length or 
quality. The rest of the reads were tracked according to their barcodes. After analyzing the results, 
the highly-yielded aptamers were tested for the free energy change (ΔG[kcal.mole-1]) of the three 
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dimensional structure using the OligoAnalyzer 3.1 Tool available online by Integrated DNA 
Technologies (IDT) website, and the most reliable ones have been chosen to be tested by the next 
step. 
 
4.3.RESULTS AND DISCUSSION 
Standard SELEX procedure has a number of limitations that intervene the overall goal of this 
procedure of selecting specific aptamers with high affinity and specificity to the target (Lakhin et 
al., 2013). The combination of randomized ssDNA library and SELEX procedure applies selection 
pressure resembles the natural selection of function-to-structure relation in RNA (Meyers et al., 
2004; Thiel et al., 2011). Conventional PCR procedure is an additional player that causes bias 
when a random library is used as the template. The resulting issues such as incorrect hybridization 
events between primer-template, template-template, and mutation are common (Katilius et al., 
2007; Spill et al., 2016). Therefore, when using random library as the template for PCR, the 
artifacts should increase logically. Eventually, the evolution of selection pressure favor the highly 
amplifying aptamer sequences over the highly specific aptamer in later SELEX cycles (Shao  et 
al., 2011; Takahashi et al., 2016; Acinas, et al., 2005; Yufa et al., 2015; Witt et al., 2017).  
Many researchers require dealing with the formation of the PCR byproducts in order to reduce the 
development of non-specific aptamers (Blind et al., 2015; Eaton et al., 2015). In the process of 
aptamers selection, there are two common artifacts in the PCR products; these are ladder-like PCR 
products and smearing band (Figure 4.1). These PCR byproducts can appear as early as in the 
second selection round during aptamer selection and increase linearly (Figure 4.2). 
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PCR byproducts formed because of several undesirable events during the aptamers amplification 
by PCR. The random design of the variable region of the library reveals multiple potential sites 
other than the primer binding regions on the library where primers can anneal (Tolle et al., 2014; 
Yufa et al., 2015). Additionally, the partial annealing of two different DNA strands could form the 
heteroduplexes, i.e. two DNA strands act synergistically with the primer(s) to produce the 
amplicon (Musheev and Krylov, 2006; Shao et al., 2011).  
In order to investigate the template-template hybridization, we amplified the library with one 
primer only (forward or reverse) (Figure 4.3). With extension using one of the primers only, ladder-
like byproduct or smear band were efficiently removed from the library. However, the length of 
the PCR products was not typical for the library length. This could be attributed to the fact that 
there are specific sequences act to hybridize to each other to act as a primer. Therefore, using one 
primer was enough to amplify these duplexes. With the presence of one primer, the complementary 
sequence act as the second primer and vice versa. Therein, the size of the PCR byproducts depends 
on the site of template-template hybridization more than the site of primer-template hybridization. 
We concluded that this byproduct could be <2X the library size at least at the first PCR cycle. 
When the cycles continue, the byproducts size increase gradually (Acinas et al., 2005; Yufa et al., 
2015; Witt et al., 2017).  
To decrease the potential of heteroduplexes formation, we sought to apply a course of thermal 
treatment for the PCR products. The upper limit of the temperature was meant to be below the 
denaturing temperature of the fully-hybridized templates and above the annealing temperature of 
the primer-template. We tested several different temperatures (data not shown) and then we chose 
to use 65ºC as the partial denaturing temperature. The rest of the thermal course is to give the 
chance for the homoduplexes to re-anneal at 20ºC (Figure 4.4). Therefore, there is no denaturing 
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for the homoduplexes due to their very low ΔG value; instead, the heteroduplexes would be applied 
under the pressure to find their correct complementary sequences. After testing different number 
of thermal cycles, we found that six cycles of the thermal correction protocol gives the best results. 
Both the ladder-like and smearing band byproducts are sensitive to the correction with this method 
and only traces of either byproducts could be detected aftermath (Figure 4.4). 
For the Illumina sequencing results, there are several stretches over the aptamers sequences where 
they were partially matching with the reverse primer sequence (Table 4.1D). This agrees with our 
prediction for the origin of the PCR byproducts and supports Tolle and co-workers (2014) results. 
In addition, there were extra-piece in the downstream where it, in most cases, expressing partial or 
full forward primer sequence, reverse primer sequence or both as an overlapping sequence (Table 
4.1A, B, C and E). 
The format of typical Illumina sequence results is shown in (Table 4.1 A). After ten round of 
aptamers selection, the common PCR byproducts are listed in Table 4.1 (B-E).  Some aptamers 
showed incorrect sequence of the reverse primer (RP). This could be attributed to the polymerase 
enzyme proofreading capacity (McInerney et al., 2014). Other aptamer sequences showed longer 
sequence than usual with the extra piece carrying partial or complete RP sequence or forward 
primer (FP) binding site sequence. This result matches with the conclusion of previous publication 
(Tolle et al., 2014). In some instances, the long extra piece showing overlapped FP binding site 
and RP sequences.  
There were short sequences that do not carry any primer sequence. Both short and long sequences 
were increasing linearly over rounds. However, PCR products that were treated with the correction 
protocol showed lower tendency to express these artifacts. In such PCR products, the short reads 
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proportion was with steep increase in the proportion in comparison to the total reads. This could 
be explained as the short reads are the results of the amplification of homoduplexes and 
heteroduplexes. Whereas, the long reads is the results of the heteroduplexes only (Table 4.2). 
Application the correction thermal cycle for the PCR products of the 10th round succeeded to shift 
this proportion toward the normal sequence size (Table 4.3). In our results, the smearing bands 
PCR byproducts were more sensitive to the thermal correction protocol than the ladder-like ones 
(Figure 4.4). This could be explained that the smearing bands are due to the formation of three-
dimensional structure hairpin whereas, the ladder-like byproduct are due to formation of 
heteroduplexes. Unfortunately, we were facing the ladder-like byproducts in our experiment 
mostly. 
 
4.4.CONCLUSIONS 
The use of PCR is the only known reliable method to exponentially amplify the enriched aptamers 
in the SELEX method. The PCR, however, could decrease the efficiency of the SELEX method 
itself due to the presence of DNA artifacts or bias over the enriched aptamers (Tolle et al., 2014; 
Thiel et al., 2011). In fact, the presence of the artifacts in the aptamers might interfere with ligand-
target interaction yield, which would result in low quality aptamers such as aptamers with no 
specificity to the target or aptamers with low affinity to the target. There are several methods are 
in use to decrease these artifacts in PCR products. PCR reconditioning is a common procedure to 
reduce the effects of these artifacts (Thiel, 2016).  
In the current article, we described a simple, yet, effective protocol to reduce the well-known 
common PCR byproducts confronting the process of SELEX. Our method treat both ladder-like 
130 
and smearing band PCR byproducts at the same efficiency. Visually, the agarose gel images 
showed that the method was capable of effective correction of the ladder-like and the smearing 
band that had been detected previously on the PCR byproducts. Similarly, the Illumina sequencing 
results showed that there was marked decrease in proportion of the short and long sequences after 
the application of this protocol. The formation of these short or long PCR byproducts might be due 
to the presence of matched sequences within the random library sequence with that of forward 
primer binding site or reverse primer sequences. Additionally, the formation of heteroduplexes 
between two random sequences within the library, could act as a primer to form multiple-length 
PCR products. Finally, the ladder-like byproducts were more refractory to correction than the 
smearing bands byproducts. 
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4.5.TABLES 
Table 4.1.  The common artifacts in PCR products after the 10 rounds of aptamers selection 
by SELEX procedure. A) The common library design with barcode included. B) Reverse primer 
(RP) shows incorrect sequence. Many aptamer sequences showed longer sequence than usual with 
the extra piece carrying partial RP sequence. C) The extra piece of a long aptamers showing 
forward primer binding site (FPBS) sequence. D) The long extra piece showing overlapped FPBS 
and RP sequences. E) Normal aptamer length with partial RP sequence. 
A    
Barcode FPBS 
Variable 
region 
RP 
CTTCGGGTATCCTCTT TCCGAATTCGAAGGACAAGAG N40 TCTTTTATGCTACGTCCCGC 
 
B    
FPBS Aptamer RP* Extra piece with RP⸸ sequence 
TCCGAATTCGAA
GGACAAGAG 
N40 TCTTTTTTTCTTCCTCCCCC (N)30-40 TCTCTTTTTCCTTCTTCTT 
*RP sequence with incorrect sequence 
⸸
Extra piece with partial RP sequence (bold font) 
C    
FPBS Aptamer RP Extra piece with FB* sequence 
TCCGAATTCGA
AGGACAAGAG 
N40 TCTTTTATGCTACGTCCCGC 
NNNNTCCGAATTCGAAGGACAAGA
G (N)20-40 
*The extra piece is with RP sequence (bold font) 
D    
FPBS Aptamer RP Extra piece with overlapped FB-RB* sequence 
TCCGAATTCGA
AGGACAAGAG 
N40 
TCTTTTATGCTACGTCC
CGC 
(N)30-40 TCTTTTATGCTACGTCCCGC 
* The extra piece showing overlapped partial FPBS binding site (large font) and RP sequence (small and bold font) 
 
E   
FPBS Aptamer with partial RP sequence RP 
TCCGAATTCGAAGGACAAGAG 
(N)20-25 
TCTTTNNTGNTACNTCCCG                          
TCTTTTATGCTACGTCCCGC 
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Table 4.2. The proportion of the short (<80nt%) and long reads (>80nt%) in comparison to 
normal length sequences (80nt%). The total reads showed that there were increase in the short 
and long read percentage in the later rounds 
Round Total reads <80nt% 80nt% >80nt% 
1 4, 441, 562 0.66 95.68 3.66 
6 4, 379, 389 1 97 2 
8 4, 087, 274 4.33 90.01 5.66 
10 3, 777, 547 23.86 67.89 9.33 
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Table 4.3. The proportion of short (<80nt%) and long reads (>80nt%) in comparison to 
normal length sequences (80nt%) with and without the course of the thermal correction. 
Round 1 used as the reference round for all lengths of sequences. 
Round Total reads <80nt% 80nt% >80nt% 
1 4, 441, 562 0.66 95.68 3.66 
10 (not corrected) 3, 777, 547 23.86 67.89 8.25 
10 (corrected) 4, 549, 398 0.88 95.56 3.56 
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4.6.FIGURES 
 
 
Figure 4.1. Patterns of PCR byproducts that occur during SELEX procedure. PCR 
byproducts appear in two different patterns on 1% agarose gel. (A) ladder-like pattern of PCR 
byproducts. (B) Smear band pattern PCR byproducts. According to the DNA library design, the 
correct size of the amplicon should be 80bp. These PCR products are from rounds 10 and 8 of the 
SELEX procedure, respectively.  
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Figure 4.2. Evolution of the PCR byproducts over the SELEX rounds. Lanes 2 represent the 
DNA library, lanes 3, 4, 5 and 6 represent PCR products from rounds 1, 2, 3, and 4 respectively. 
PCR products were loaded on 1% agarose gel.  
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Figure 4.3. Amplification of aptamers pool with single primer. Aptamers form round 6 was 
used as a template for PCR. The process of amplification was carried out using forward primer 
alone (lane 2, 45 thermal cycles), reverse primer alone (lane 3, 45 thermal cycles), forward primer 
alone (lane 4, 30 thermal cycles), or forward and reverse primers together (lane 7, 45 thermal 
cycles). Lanes 5 and 6 represent negative controls with no template or no primer, respectively. 
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Figure 4.4. Application of thermal cycles to correct PCR byproducts. (A): PCR byproduct 
from the 10th enrichment cycle of SELEX procedure. The PCR byproducts appear as a ladder-like 
smear pattern (lane 2). The correction protocol included application of 65ºC for 10min, followed 
by 20ºC for 1min for 1, 2, 3, 4, 5 and 6 cycles (lanes 3-8, respectively). (B): correction of smearing 
band PCR byproducts by applying 6 cycles of the thermal protocol (lane 2 before and lane 3 after 
the correction).  
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CHAPTER V 
5.1. CONCLUSIONS AND SIGNIFICANCE 
Restrictions and strict scrutiny on antimicrobial use with absence of effective antiviral remedies in 
commercial poultry expose the vaccines as the main tool to confront the infectious agents 
(Kennedy and Read, 2017; Kennedy and Read, 2018). Traditional vaccines act to stimulate less 
effective immune responses, mainly, due to low specificity or/and low immune enhancing 
capacities of their accompanying adjuvants. Assembling an efficient vaccine with potent adjuvants 
is demanding due to emerging of low-immunogenic and more sophisticated vaccines such as 
subunit vaccines (Nobel, 2013).  
The studies presented in this dissertation aimed to determine the ability of DNA aptamers-based 
RCA products to act as an immunological adjuvant in broiler chickens. In Chapter II, I describes 
the development of agonistic DNA aptamers to chicken CD40 receptor. We hypothesized that 
ligation of CD40 receptor on macrophages with DNA aptamers would promote activation of these 
cells. First, we prepared the candidate aptamers in form of RCA products to combine the specificity 
of our aptamers with the higher affinity and large spanning are offer by the RCA products. These 
aptamers were capable to induce stimulation of chicken macrophage HD11 cell line characterized 
by dose-dependent nitric oxide liberation. In addition, I have shown the actual sites where these 
aptamers interact with the target protein, herein, specified the active sites on the receptor.  
Several attempts have achieved to develop CD40 agonistic adjuvants, mainly, by developing 
monoclonal antibodies in mammalian models (Carlring et al., 2004; Smyth and Kershaw, 2011; 
Thompson et al., 2015). Recent publications from our lab showed that anti-CD40 monoclonal 
antibody-based adjuvant could guide robust immune response when loaded with hapten peptide 
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(Chen et al., 2010; Chen et al., 2012; Chou et al., 2016). Traditionally, adaptive immune response 
ignition requires the interaction of TCR on the resting lymphocytes with peptide/MHC class II 
molecule on APCs as the first signal. Once the first signal sparked, activation of both the T 
lymphocyte and the APC with concurrence upregulation of costimulatory molecules and cytokines 
accompanies.  Follows, the second signal comes from costimulatory molecules, such as CD40, 
CD80, on the APCs with cognate ligands on activated T lymphocytes. Costimulatory molecules-
ligands interaction optimizes the T lymphocytes and APCs activation. The third signal comes from 
the cytokines that have releases by the two types of the activated immunological cells.  
When B cells present the foreign antigen to the T cell, activated B cells trigger the differentiation 
of a subset of TH cells called follicular helper T cells (TFH) in the lymphoid follicles. The TFH, in 
turn, mediate B cell differentiation and proliferation. CD40-CD40L interaction plays crucial role 
in this two-way activation pathway and formation of germinal centers. Commonly, in the dark 
zone within the germinal centers of lymphoid follicles, B cells proliferate, differentiate and expand 
within the light zone of the germinal centers. This is accompanied by emerging of long-living 
memory B cell sand antibody-producing plasma cells with antibody class switching and antibody 
affinity maturation (Crotty, 2012; Mesin et al., 2016; Vaccari and Franchini, 2018). However, 
CD40 receptor interaction pathways within these immune cells is only discussed briefly in 
mammalian species, we only predict the same effects in avian species.  
The study discussed in Chapter III presents the use of the DNA aptamers specifically selected 
against the chicken CD40 receptor in vitro to act as adjuvant when engaged with low immunogenic 
peptide hapten. Encouraged by the results from the first experiment (Chapter II), we proceeded to 
develop an immune complex composed of the enriched aptamers (in form of RCA products) in 
conjugation with peptide hapten. These aptamers should be replacing the agonistic anti-CD40 
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MAb that our lab group developed recently. To determine the ability of our DNA aptamers to work 
as an adjuvant, we created an immune complex composed of RCA-streptavidin-peptide. We 
sought to use M2e peptide in our immune complex. M2e is a conserved peptide among influenza 
viruses and it is known to induce no or low immune response by its own.  
Our immune complex showed ability to stimulate the production of anti-M2e IgG in chicken sera 
as early as 7 days post immunization. This antibody titer remained high until the age of 35 days 
28 days post immunization. However, the lower dose of the same immune complex needed a boost 
to sustain a detectable anti-M2e IgG titer. In essence, the immune complex could have been created 
easier if we selected DNA aptamers against biotin to replace the streptavidin. However, the 
streptavidin is high molecular weight protein that creates immune response by its own and may 
interfere with final immune response (Meyer et al., 2000; Yumura et al., 2012).  
Chapter IV presents an effective method for correction the PCR byproducts that confront the use 
of SELEX procedure as the main tool to develop DNA aptamers. When multi-sequence template 
used to develop PCR, as in the use of DNA library to select aptamers, heteroduplexes formed 
considerably. The formation of these heteroduplexes is due to partial matching and hybridization 
among different sequencing within the library pool or due to incorrect primer-template 
hybridization site. For either cause, the high variability of the DNA library promotes these 
undesirable hybridization. Anyway, the PCR byproducts may take ladder-like shape or smearing 
bands. These byproducts affect the yield and quality of the enriched aptamers.  In this chapter, I 
described a simple and effective thermal correction course that was applied to reduce the 
heteroduplexes formation in the PCR products. The thermal correction course composed of six 
cycles of elevation the temperature of the purified PCR products to 65°C for 10min and then cool 
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them down to 20°C for 1min, with no need for enzymatic treatment. The results confirmed high 
quality DNA yield of this method in all samples.  
Taken together, our results suggest that our DNA aptamers are qualified candidate for 
immunological adjuvant in chickens. These aptamers could be considered signal-2 enhancers 
because they facilitate an acquired immune response at the level of costimulatory molecules. Using 
low immunogenic DNA aptamers as adjuvants could mount better immune response, increase the 
safety of vaccines and offer better mate for subunit vaccines. In addition, using DNA aptamers-
based adjuvant would simultaneously lower the cost of many modern vaccines. 
The significance of this dissertation, as we proved, that ligation of CD40 receptor on APCs 
promotes induction of acquired immune response in chickens. At least, we showed this in 
macrophages and B-lymphocytes.  
As mentioned earlier, tumor-associated macrophages (TAMs) promote tumor cells proliferation 
and metastasis by enhancing angiogenesis within the tumor mass and by inhibiting the T-cell 
dependent anti-tumor immunity. The ligation of CD40 receptor on TAMs would revert their 
tumor-enhancing activity and suppressive effect on immune response in mammals. Several 
chemokines and cytokines are responsible for attraction of monocytes to tumor microenvironment 
and polarizing these monocytes into TAMs such as macrophages colony-stimulating factor and 
IL-4 and IL-10. However, the mechanisms by which TAMs enhance tumor metastasis are poorly 
understood (Wang and Joyce. 2010; Liu and Cao, 2015; Hoves et al., 2018).   
In chicken, we know that macrophages play crucial role in the pathogenesis of lymphoid leucosis 
and Marek’s disease infections. In lymphoid leucosis, medullary macrophages appear to enhance 
the virus replication and transmission to the lymphoid cells in the bursa of Fabricius. In addition, 
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macrophages suppress immune response by suppressing the normal spleen cells response in 
Marek’s disease (Lee et al., 1978; Gilka and Spencer, 1987; Barrow et al., 2003).   
Apart from using our aptamers as immunological adjuvant, these aptamers would provide 
spectacular input for dealing with oncoviruses infections in chicken such as lymphoid leukosis and 
Marek’s disease. These aptamers could polarize macrophages, herein; revert their suppressive 
effect during the pathogenesis of these diseases (Wang et al., 2018; Chakraborty et al., 2019).  
The knowledge we have that the ligation of the CD40 receptor on the tumor-associated 
macrophages reverts their tumor enhancing activity and render them active antitumor cells. 
Therefore, the aptamer-RCA coupling might have an impact on mammalian cancer research as 
well.  
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